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ABSTRACT

DEVELOPMENT OF A KINETIC MODEL TO INVESTIGATE THE EFFECT OF
COMPOSITIONAL VARIATION AND A PROCESSING CONDITION ON THE
SOLID-STATE DEGRADATION OF GABAPENTIN

By
Akshata A. Nevrekar
August 2015

Dissertation supervised by Ira S. Buckner, Ph.D.
Gabapentin is used in the treatment of seizures and neuropathic pain. Gabapentin
undergoes intra-molecular cyclization to form a γ-lactam. The product lactam is twenty times
more toxic than gabapentin, causing seizures in animal models. The United States Pharmacopeia
(USP) limits the content of lactam in gabapentin formulations to 0.4% w/w. A number of patents
have been issued for solid dosage forms formulated to stabilize gabapentin. Despite these efforts,
factors contributing to gabapentin’s poor stability in the solid-state have not been explored
completely.
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It was hypothesized, that physicochemical properties of the excipients and compaction pressure
will accelerate the solid-state degradation of gabapentin, increasing the kinetic rate constant for
lactam formation. To test the hypotheses, binary mixtures and compacts of gabapentin with
different excipients were prepared and stored under accelerated study conditions. The
concentration of lactam and gabapentin was measured using a validated analytical method. A
concentration dependent catalytic effect by the excipients was determined by mixing different
concentrations of the excipient with gabapentin. The effect of excipient particle size was
determined by mixing different size fractions of the excipient with gabapentin.

Significant degradation of unprocessed gabapentin in the presence of excipients strongly
suggested a catalytic role of the excipients on gabapentin’s degradation. The existing model was
expanded to account for the observed catalytic effect of excipients. A relationship was developed
between the rate constant for lactam formation and physical properties of the excipients (such as
particle size, morphology, molecular weight, molecular cross sectional area and specific surface
area). Along with the catalytic effect of the excipients, compaction pressure and powder
properties of the excipients such as moisture content, particle size and yield pressure appeared to
be other potential contributing factors affecting gabapentin’s degradation.
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Chapter 1
Introduction
Solid-state degradation reactions occur commonly in drug substances and their formulations.
These reactions occur due to a drug being intrinsically active or unstable.1,2 The degradation of
drug molecules is typically accelerated by compositional factors, such as the presence of
excipients, environmental conditions and exposure of drug molecules to processing conditions.2

Excipients can potentially accelerate the degradation reaction by interacting chemically with
drug molecules. An example of such an interaction would be acid-base reaction between an
acidic drug and a basic excipient. Amorphous excipients, or excipients with greater noncrystalline content, possess enhanced molecular mobility and ability to interact with water,
resulting in accelerated drug degradation.2,3 Environmental conditions such as temperature and
humidity can accelerate drug degradation by increasing kinetic energy and molecular mobility of
the system.2,4 Environmental moisture can stabilize drug degradation by facilitating “selfhealing” of crystal defects induced during processing.5 Processing conditions involve energy
input which induces changes in particle size, crystallinity, surface area and crystal form, resulting
in modification of physical and chemical properties of a drug molecule.6-11 Application of stress
on a drug crystal during processing creates lattice defects, which act as sites to initiate
degradation reactions. These lattice defects can also contribute to lattice disorder, leading to
different packing arrangements and conformations within a crystal, making conditions favorable
for interaction.2,12-14 Hence, compositional, environmental and processing factors are critical in
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determining the solid-state degradation of a drug and its dosage forms. Establishing drug stability
and reactivity by taking the above factors into consideration becomes an important criterion for
designing a stable formulation, ascertaining shelf life, patient safety, storage conditions and
optimizing manufacturing processes.15 The present research explores the underlying effects of
compositional and processing factors affecting the solid-state degradation of the model drug
gabapentin.

1.1 Statement of Problem
Gabapentin, [1-(amino methyl) cyclohexane acetic acid] is a γ-aminobutyric acid (GABA)
analogue used in the treatment of epilepsy and neuropathic pain.16,17 It is also used in treatment
of bipolar disorder and is effective in reducing spasticity associated with multiple sclerosis.15 The
primary reason for its extensive commercial usage is milder side effects relative to older
generation anti-epileptic agents.18
Gabapentin undergoes degradation by nucleophilic attack of the alkyl amine on the carboxylate
carbon to form γ-lactam [3, 3-petamethylene-4-butyrolactam] as shown in Figure 1.15

Figure 1: Intramolecular cyclization reaction for the conversion of gabapentin to lactam
The degradation product, “lactam”, is known to be 20-times more toxic than gabapentin itself
and has been reported to cause seizures in animal models.19 The United States Pharmacopeia
2

(USP) has recommended that the concentration of lactam in any gabapentin formulation should
not exceed 0.4% w/w.5 Gabapentin is available commercially as either a tablet or a capsule
dosage form each of which includes a number of different excipients. Hard gelatin capsules are
available for a single dose, containing between 100-400 mg gabapentin, while elliptical film
coated tablets are available for a single dose of 600-800 mg gabapentin.20

In 2007, a voluntary recall of 73 million gabapentin tablets was announced by Ranbaxy
Pharmaceuticals for exceeding the lactam impurity specifications of gabapentin formulations.21
Thereafter, a number of patents have been filed to formulate a more stable dosage form
containing gabapentin.22-27

Literature findings7,34 have indicated that excipient type, pH conditions and buffering salt
concentration may effect the degradation kinetics of gabapentin in solution. The possibility of a
similar catalytic reaction (due to excipients, pH, salt concentration) in the solid-state, mediated
by common excipients used to formulate gabapentin, requires further exploration. Hence,
providing evidence for the role of excipient properties affecting the degradation of gabapentin
needs to be attempted.

Considering the commercial availability of gabapentin as tablets along with the excipients, the
effect of compression pressure on the degradation kinetics needed investigation. Compaction as a
processing condition could potentially increase the concentration of reactive molecules within
gabapentin crystals, accelerating lactam formation. Therefore, the present reaserch will help
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investigate the effect of excipient properties and compaction conditions affecting the solid-state
degradation of gabapentin.
1.2. Hypothesis and Specific Aims
Stemming from the previous research conducted on the solid-state degradation of gabapentin, the
objective of this work was to develop an understanding of the role of excipients and
compaction as a processing condition on the solid-state degradation of gabapentin. The
research primarily focuses on determining the role of excipient concentration and their physicalchemical properties on gabapentin’s degradation. The research will also help to identify other
potential factors associated with powder properties of excipients and compaction conditions
impacting gabapentin’s degradation.
The experiments were designed to test the central hypothesis, that physicochemical properties
(such as specific surface area, molecular weight, particle size, particle shape and, acidic or
basic strength) of the excipients will accelerate the solid-state degradation of gabapentin,
increasing the rate constant (k2) for lactam formation. The degradation kinetics,
predominantly the initial rate of lactam formation, will be further accelerated by
compaction of the gabapentin-excipient physical mixtures.

The overarching objective of the project is to use the research findings to develop a risk
assessment tool, which would have the ability to predict the amount of lactam generated over a
predetermined time frame in gabapentin formulations, in the presence of varying excipient
properties and compaction conditions.
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1.3. Literature Review
1.3.1. Model Compound Gabapentin
Gabapentin is an achiral γ-amino acid, which has the propensity to undergo intramolecular
cyclization to form a lactam molecule. The ability to undergo cyclization has been attributed to
the close proximity between the amine and the carboxylic group in the gabapentin molecule.28

Gabapentin was derived by adding a cyclohexyl group to the γ-amino butyric acid backbone.19
Gabapentin is a white to off-white colored crystalline solid with a melting point of 165°C. It is
freely soluble in water (~150 mg/ml at pH 7.4) under both acidic and basic conditions. It is a
BCS class III drug with a log partition coefficient (n-octanol/0.05 M phosphate buffer pH 7.4) of
-1.25.20 Gabapentin has a molecular weight of 171.24 g/mole, and pKa1 of 3.7 and pKa2 of 10.7
respectively.5 It is a low potency drug and is typically dosed at high concentrations to provide the
necessary pharmacological effect.29 The absorption of gabapentin in the brain is delayed because
of its inability to passively diffuse the blood brain barrier (BBB).19 It is transported to the brain
by saturable transporters.19 Gabapentin is toxic at concentrations of 8000 mg/kg. In the solidstate, gabapentin exists in its zwitterionic form, while in solution, it exists as cationic, anionic,
zwitterionic and neutral species depending on the pH of the solution.30 The lactam degradation
product is a white crystalline solid with a melting point of 85°C.83 Lactam is toxic at a
concentration of 300 mg/kg.23

Pharmacology: Gabapentin is a GABA analogue that does not bind to GABA receptors or alter
the metabolism of GABA in the brain. The binding sites for gabapentin are located on neurons in
the brain that are rich in glutaminergic synapses. Gabapentin is also a weak inhibitor of the
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branched chain aminotransferase enzyme involved in glutamic acid synthesis in the brain.19 The
therapeutic action of the drug is thought to involve voltage gated calcium ion channels. 15 Less
than 3% of the administered drug is bound to the plasma proteins, and approximately 20% of the
drug concentration is available for cerebrospinal fluid (CSF) circulation.20 Elimination of
gabapentin from the systemic circulation occurs via renal excretion and the half-life in the body
is between 5-7 h. 20

1.3.2. Previous studies on gabapentin
Physical Stability of gabapentin
Four solid forms of gabapentin have been reported in the literature.31 The commercially available
Form II is anhydrous, and is the most thermodynamically stable. Form I (monohydrate) is the
most stable form in aqueous conditions, while Form III has a unique intramolecular hydrogen
bond between the amine and the carboxylic groups. Form IV is hypothesized to be the last
transformed polymorph of gabapentin before its intramolecular cyclization to the lactam
molecule.30,32,33

Progressive polymorphic transformation was observed upon heating gabapentin from ambient
temperature to its melting temperature. It was observed that as gabapentin Form I is heated above
its melting temperature it dehydrates and transforms to Form III followed by Form IV. In
contrast, heating Form II and Form III under similar conditions, results in direct transformation
to both Form IV with some degradation to lactam.32
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Commercially available Form II is physically stable in up to 50% RH conditions while Form III
and Form IV transform to Form II under similar humidity conditions. At 100% RH conditions all
the anhydrous Forms (Form II, III, and IV) of gabapentin transform to the monohydrate.

Grinding and kneading results in polymorphic conversion of gabapentin Form III and Form IV to
Form II, however gabapentin Form II remains physically stable under these conditions. Form I,
on the other hand, undergoes transformation to Form III at elevated temperatures (50°C) and
Form IV under desiccated conditions.21 The above results indicate the physical stability of
gabapentin Form II (used in the presented research) under the accelerated environmental
conditions (50°C / 5% RH) and the physical mixing used in the presented research.

Inter-conversion between polymorphic forms of gabapentin has been observed when it is
exposed to processing conditions such as milling (ball mill), and accelerated temperature
conditions (50°C) in the presence of excipients. It was observed that co-milling gabapentin for
120 min along with excipients, (such as calcium phosphate dihydrate, magnesium stearate,
cyclodextrins, mannitol and corn starch), did not cause any polymorphic transformation of the
stable Form II, while co-milling with excipients, (such as microcrystalline cellulose,
hydroxypropylmethylcellulose (HPMC) and Kollidon® K-30), demonstrated polymorphic
transformation from Form II to Form IV. Co-milling gabapentin with fumed silicon dioxide and
talc resulted in conversion of Form II to Form IV and a significant amount of lactam. The
polymorphic conversion of gabapentin was thought to be induced by co-processing gabapentin
with excipients.7 The type of excipient processed with gabapentin seemed to affect the
transformation. The energy used in co-milling the materials increased the mobility of gabapentin
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molecules to facilitate form change. Additionally, the nature (hard/soft) of excipients co-milled
with gabapentin contributed to the increased molecular mobility and accelerated form
conversion. It is important to note the potential role of excipient type in driving the polymorphic
conversion of processed gabapentin. The findings of the above study are especially important
when determining the effect of excipient type especially its nature on the solid-state degradation
of compacted gabapentin in the presented research.

Chemical Instability of Gabapentin in Solution State
Gabapentin was found to be unstable in aqueous solution and capable of undergoing cyclization
to form the lactam degradant.7,34 Heating a buffered solution (0.025-0.1M) of gabapentin at
80°C resulted in accelerated lactam formation (Figure 2). A plateau of maximum reaction rate
for lactam formation was reached when the amine was present as a free base (nucleophile). A
27-fold decrease in the reaction rate was observed after increasing the amount of protonated
amine. The pH-rate profile for the reaction showed a minimum degradation rate at neutral pH
conditions (pH 6-7) and significant reactivity at both acidic pH (pH 2.2) and basic pH conditions
(pH >10) 7,34.

A scheme for lactam formation in solution under different pH conditions was proposed in
Figure 3. In this scheme, the neutral amino group acts as a nucleophile, attacking the
deprotonated carboxyl carbon, to drive lactam formation. The zwitterionic and the cationic forms
of gabapentin on the other hand are relatively less reactive.34 The observed reactivity at low pH
was thought to be due to the attack of the free amino group on the protonated carboxyl group,
leading to formation of a neutral tetrahedral intermediate (T0) as seen in Figure 3. General acid
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catalysis resulted in breakdown of the intermediate form by addition of a proton provided by the
buffering species to the leaving hydroxyl group.

The kinetics for lactam formation were observed to be dependent on buffer concentration
(general base catalysis), buffer type (sulfate, acetate, phosphate, and borate) and pH conditions.
The lactam formation was catalyzed (specific base catalysis) under both acidic and basic pH
conditions.15 This solution state degradation of gabapentin catalyzed by the above mentioned
factors was further accelerated by increasing temperature conditions.32,35,36

Figure 2: Solution state degradation of gabapentin under different pH conditions.15 An
accelerated lactam formation was observed under both acidic and basic pH conditions.
“Reprinted from Tetrahedron, volume 64, issue 28, Zambon Elena, Giovanetti Roberto, Cotarca
Livius, Pasquato Lucia. Mechanistic investigation on 2-aza-spiro[4,5]decan-3-one formation
from 1-(aminomethyl)cyclohexylacetic acid (gabapentin), pp 6739-6743, Copyright (2008), with
permission from Elsevier.”
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Figure 3: Mechanism for the degradation of gabapentin in solution.15 The zwitterionic form
(B) and the protonated form (A) are less reactive than the unprotonated form (C).
“Reprinted from Tetrahedron, volume 64, issue 28, Zambon Elena, Giovanetti Roberto, Cotarca
Livius, Pasquato Lucia. Mechanistic investigation on 2-aza-spiro[4,5]decan-3-one formation
from 1-(aminomethyl)cyclohexylacetic acid (gabapentin). pp 6739-6743, Copyright (2008), with
permission from Elsevier.”
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Chemical Instability of Gabapentin in the Solid-State
Gabapentin was found to be susceptible to milling-induced chemical instability. This instability
was attributed mainly to the formation of crystal defects, which increased the concentration of
reactive gabapentin molecules. These reactive molecules, primarily comprising of the surface
molecules and other damaged molecules in the bulk of the crystal, were capable of
spontaneously converting to lactam at a faster rate compared to the less reactive molecules
(stable) in the bulk of the crystal.5 The increased rate (500-fold) of lactam formation on milling
was credited to the combined effects of enlarged surface area, duration of milling and in-process
lactam levels.1,5

The presence of environmental moisture was seen to stabilize milled gabapentin by enabling
healing of crystal defects incorporated during milling.5 Healing of crystal defects was further
expedited by surface adsorbed moisture.5 Milled gabapentin particles demonstrated higher
stability when stored under relative humidity conditions greater than 31%.

Conversion of lactam back to gabapentin, was found to be irreversible under varying conditions
of humidity (31-81% RH), temperature (50°C, and 80°C) and in buffered solutions
(pH 2.2, 7.0, 8.5).5 These results highlighted that conversion of lactam back to gabapentin only
occurs under harsh conditions and is less likely to occur under the accelerated study conditions
used in our research to test gabapentin’s stability. However, the role of excipient moisture on the
degradation of gabapentin needs to be further studied considering, the ability of moisture to
either stabilize gabapentin or potentially accelerate the catalytic effect of the excipients.
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Solid-State Stability of Gabapentin Co-Processed with Excipients
A study investigated lactam formation in lyophilized blends of gabapentin with cyclodextrins,
lactose, polyvinyl pyrrolidone (Kollidon® K-30), mannitol, trehalose and D-raffinose.37 The
mixtures were maintained at 50°C and variable humidity conditions (0, 45, 75% RH).
Accelerated lactam formation was not observed when gabapentin in its freeze dried form was
maintained under accelerated temperature and humidity conditions in the absence of excipients.
Amongst the excipients lyophilized with gabapentin, highest lactam formation was observed in
mixtures of gabapentin with cyclodextrins, especially HP-β-cyclodextrin. The accelerated
lactamization was attributed to the restricted conformational freedom between the reacting
functional groups of gabapentin as a result of inclusion complexation. Increasing humidity was
seen to further accelerate lactam formation, due to moisture facilitating inclusion of gabapentin
in the cavity of cyclodextrin. Accelerated lactam formation was observed in case of lyophilized
blends of gabapentin with Kollidon® K-30 and lactose. A possible explanation for the effect of
lactose was thought to involve Maillard reaction and successive Amadori rearrangement between
lactose and the primary amino group of gabapentin. However, lyophilized mixtures of
gabapentin and sugars did not show accelerated lactam formation. The study however speculated
reasons for the effect of excipient type but was not able to clearly separate the effect of excipient
properties from other convoluting effects of lyophillization.37 The presented research will further
explore the effect of excipient properties affecting the kinetics of lactam formation in the absence
of any processing conditions.
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Kinetic Model for Solid-State Degradation of Gabapentin
A quantitative solid-state kinetic model (Figure 4) has been developed, that accounts for the
mechanistic effects of environmental conditions and processing conditions (milling) on the
degradation of gabapentin.1 The degradation was successfully described by rate constants k1
(h-1mol-1) for autocatalytic branching, k2 (h-1) for spontaneous dehydration, k3 (h-1mol-1) for
moisture induced recovery or branching termination and gaba0* (% mole), which represented
chemically intact gabapentin molecules with greater reactivity or mobility present inherently in
the crystal. The kinetic model assumes formation of lactam by spontaneous conversion of gaba*.1
Equations 1-3 describe the kinetics for the solid-state degradation of gabapentin.1

Figure 4: Kinetic scheme describing solid-state degradation of milled gabapentin stored
under accelerated temperature and humidity conditions.1 “(Kinetic Model for Solid-State
Degradation of Gabapentin. J. Pharm. Sci., Vol. 101, pp 2123-2133), by Zong. Z., Qui. J.,
Tinmanee. R., Kirsch. L.E. Copyright (2012) by Wiley periodicals, Inc.. Reproduced with
permission from Wiley periodicals, Inc. via Copyright Clearance Center.”

𝐝[𝐠𝐚𝐛𝐚]
= −𝒌𝟏 [𝒈𝒂𝒃𝒂][𝒈𝒂𝒃𝒂∗ + 𝑳] + 𝒌𝟑 [𝒈𝒂𝒃𝒂][𝒈𝒂𝒃𝒂∗ ]
𝐝𝐭

Equation 1

𝐝[𝒈𝒂𝒃𝒂∗ ]
= 𝒌𝟏 [𝒈𝒂𝒃𝒂][𝒈𝒂𝒃𝒂∗ + 𝑳] − 𝒌𝟑 [𝒈𝒂𝒃𝒂][𝒈𝒂𝒃𝒂∗ ] − 𝒌𝟐 [𝒈𝒂𝒃𝒂∗ ]
𝐝𝐭

Equation 2

𝐝[𝐋]
= 𝒌𝟐 [𝒈𝒂𝒃𝒂∗ ]
𝐝𝐭

Equation 3
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A typical degradation profile for milled gabapentin under accelerated environmental conditions
(40°C / 5% RH) was described by two predominant phases (Figure 5). The first phase ((1) Figure
5) primarily involved the initial lactam formation due to rapid conversion of the reactive
gabapentin molecules inherently present in the sample (gaba0*). This was followed by the second
phase ((2) Figure 5), described by a combination of disorder propagation, moisture induced
termination and chemical conversion of gabapentin to lactam.1 The model involved consecutive
processes of crystal defect propagation and spontaneous conversion of gabapentin to lactam. The
kinetics for gaba* formation were described as an autocatalytic process with the rate being
catalyzed by the concentration of gaba* and lactam.

Figure 5: Degradation profile for milled gabapentin under accelerated storage conditions.
The degradation profile on the left of the dotted line (1) denotes the initial rate of lactam
formation predominantly described by rate constant k2 and gaba0*. The degradation profile
on the right of the dotted line (2) is predominantly described by rate constants k1 and k3.
This phase represents the autocatalytic branching or moisture induced termination phase
in the degradation kinetics. “(Kinetic Model for Solid-State Degradation of Gabapentin. J.
Pharm. Sci., Vol. 101, pp 2123-2133), by Zong. Z., Qui. J., Tinmanee. R., Kirsch. L.E.
Copyright (2012) by Wiley periodicals, Inc.. Reproduced with permission from Wiley
periodicals, Inc. via Copyright Clearance Center.”
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In summary, the cyclization reaction is believed to initiate at imperfection sites within the crystal
lattice. As the concentration of reactive gabapentin molecules is consumed, the reaction
propagates due to the generation of new nuclei at lactam and gabapentin molecular interfaces.
Environmental temperature conditions impact rate constants k1, k2, k3, while moisture conditions
have a predominant effect on rate constant k3. Extended Arrhenius equation (Equation 4-6)1 was
used to estimate the rate constants for gabapentin’s degradation after milling as a function of
environmental conditions in the absence of excipients.1
𝒌𝟏 = 𝟏. 𝟒𝟖 × 𝟏𝟎𝟏𝟎 × 𝐞𝐱𝐩(−

𝟏𝟎𝟕𝟎𝟕
)
𝑻

Equation 4

𝒌𝟐 = 𝟐. 𝟒𝟎 × 𝟏𝟎𝟗 × 𝐞𝐱𝐩(−

𝟖𝟐𝟗𝟓
)
𝑻

Equation 5

𝒌𝟑 = 𝟐. 𝟏𝟓 × 𝟏𝟎𝟔 × 𝐞𝐱𝐩(−

𝟖𝟏𝟔𝟑
) × 𝐞𝐱𝐩(𝟎. 𝟎𝟗𝟐𝟑 × % 𝑹𝑯)
𝑻

Equation 6

Milling duration impacted the value of gaba0*, which was estimated to vary between
0.46-1.04% mole for gabapentin samples milled between 15-60 min.1 The study clearly
demonstrated that the processing increased the concentration of reactive gabapentin molecules.

The above equations can be used to estimate the value of rate constants and the concentration of
reactive gabapentin molecules after processing and varying the environmental conditions. In the
presented research, the estimates would be used to establish a range for the initial parameter
values during parameterization of the data, using non-linear regression.

1.3.3. Commonly Used Pharmaceutical Excipients
The chemical structures or formulae for all the excipients procured in the study are provided in
Table 1.
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Table 1: Structural Information for the Excipients used in the Study38
Excipient chemical name
Dibasic calcium phosphate
dihydrate
Dibasic calcium phosphate
anhydrous
Tribasic calcium
phosphate
Monobasic calcium
phosphate

Common name

Structure / chemical formula

Emcompress®

Ca(HPO4)·2H2O

A-Tab®

Ca(HPO4)

Tri-Tab®

Ca5OH(PO4)3/10CaO3P2O5·H2O

Mono-Tab

Ca(H2PO4)2

Starch

Unipure® DW

HPC

Klucel® EF
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HPMC

Methocel®

Magnesium silicate

Talc

Dibasic calcium phosphate anhydrous (A-Tab®) and Dibasic calcium phosphate dihydrate
(Emcompress®)
The major pharmaceutical application of dicalcium phosphate is that of a diluent in tablet and
capsule formulation due to its good compaction and flow properties. Its predominant
deformation mechanism is by brittle fracture. The molecular weight of A-Tab® is 136.06 g/mole
and that of Emcompress® is 172.09 g/mole. Dicalcium phosphate is non-hygroscopic and is
stable at room temperature. The anhydrous grade does not transform to the dihydrate form.
However, the dihydrate form can lose its water of crystallization under high temperature and low
humidity conditions. The true density of the anhydrous grade of dicalcium phosphate is around
2.89 g/cm3, while bulk and tap densities are 0.78 g/cm3 and 0.82 g/cm3 respectively. The true
density of the dihydrate form is 2.38 g/cm3 and bulk and tap densities are 0.91 g/cm3 and 1.17
g/cm3 respectively. The average particle size diameter is around 180 μm for both the anhydrous
and the dihydrate form. The specific surface area (20-30 m2/g) for the anhydrous form is greater
relative to the specific surface area (0.44-0.46 m2/g) for the dihydrate form. The excipient is
known to be incompatible with tetracycline antibiotics and drugs such as indomethacin, aspirin,
aspartame, ampicillin, cephalexin, and erythromycin.38
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Tribasic Calcium Phosphate (Tri-Tab®)
Tri-Tab® is used in the pharmaceutical industry as an anti-caking agent, glidant, diluent and
binder in case of direct compression or wet granulated formulations. In some cases, the excipient
is also used as a tablet disintegrant and as a major source of calcium and phosphorus. Its primary
bonding mechanism is by plastic deformation.38
Tribasic calcium phosphate is available in two forms 1. Ca(PO4)2 with a molecular weight of
310.20 g/mole and 2. Ca5(OH)(PO4)3 with a molecular weight of 1004.70 g/mole. In the
dissertation studies, the second form of Tri-Tab® was used. The true density of the material is
3.14 g/cm3 while, bulk and tap density values are 0.3-0.8 g/cm3 (powder form-granular form) and
0.95 g/cm3 respectively. The melting point is 1670°C, providing stability to the material under
high temperature conditions. Specific surface area of the material is 70-80 m2/g. The material is
slightly hygroscopic (2% moisture content, under 15-65% RH conditions) as the surface
moisture is picked up and contained within small pores in the crystal structure. The excipient is
available with an average particle diameter of 350 μm and is known to be incompatible with
tetracycline antibiotics and tocopheryl acetate.38

Hydroxypropyl Cellulose (HPC/Klucel®)
Hydroxypropyl cellulose (HPC/Klucel®) is partially substituted poly (hydroxypropyl) ether of
cellulose, containing not more than 0.6% silica or other anticaking agent. The excipient is used in
the pharmaceutical industry as a coating agent for extended release formulations, binding agent,
stabilizing agent, emulsifying agent and viscosity enhancing agent.
The

molecular

weight

is

dependent

on

the

chain

length

and

varies

between

50,000-12, 50,000 g/mole. The material has a bulk density of 0.5 g/cm3 and a glass transition
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temperature of 130 °C. The material decomposes between 260-275°C. The material is slightly
hygroscopic adsorbing about 4% w/w moisture at 50% RH conditions and 12% w/w moisture at
84% RH conditions. The material is known to be incompatible with substituted phenol
derivatives, methyl and propyl paraben.38

Hydroxypropyl Methyl Cellulose (HPMC, Methocel®)
Hydroxypropyl methyl cellulose is used in the pharmaceutical industry as a bio-adhesive
material, coating agent in controlled release formulations, dissolution enhancing agent,
emulsifying agent, dispersing agent, film forming agent and in extended and modified release
formulations. It is available as several grades varying in their molecular weight between
10,000-15,00,000 g/mole and one to two degrees of substitution. The degree of substitution
denotes the amount of substituent groups on the anhydroglucose units of cellulose. True density
of the material is 1.32 g/cm3 and bulk and tap density are 0.34 g/cm3 and 0.55 g/cm3 respectively.
Glass transition temperature of HPMC is between 170-180°C, and it decomposes at
approximately 230 °C. It is slightly hygroscopic and absorbs ~10% moisture at relative humidity
conditions of 70%. HPMC is known to be incompatible with oxidizing agents, and is known to
form a complex with metallic salts or ionic organics to form insoluble precipitates.38

Pregelatinized Starch
Pregelatinized starch (Unipure®) is chemically or mechanically processed to rupture all or parts
of the starch granules. Partial gelatinization renders starch flowable and directly compressible,
while full gelatinization produces cold water soluble starch which is mainly used as a wet
granulating agent. Pregelatinized starch, is known to contain 5% free amylose, 15% free
amylopectin and 80% unmodified starch. It is used in the pharmaceutical industry as tablet or
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capsule diluent, disintegrant and tablet binder. In comparison to starch, pre-gelatinized starch
possesses enhanced flow properties and compression characteristics. The material deforms
predominantly by plastic flow accompanied by substantial elastic deformation.38 The true density
of pre-gelatinized starch is 1.51 g/cm3 and bulk and tap densities are approximately
0.58 g/cm3 and 0.87 g/cm3 respectively. Pre-gelatinized starch is hygroscopic and absorbs
approximately 15% w/w moisture at 70% RH conditions. Mean particle diameter is around
52 μm and specific surface area varies between 0.18-0.28 m2/g.38

Talc
Talc is purified, hydrated magnesium silicate with a molecular formula of Mg(Si2O5)4(OH)4. It
may contain variable amounts of iron and aluminium silicate as impurities. It is used in the
pharmaceutical industry as an anticaking agent, glidant, tablet and capsule diluent, lubricant and
dissolution retardant in controlled release formulations. Talc adsorbs insignificant amounts of
moisture at 90% RH conditions and ambient temperature conditions. Almost 99% of talc
particles pass through sieve number 44 (355 µm) and have a specific surface area of
2.41-2.42 m2/g. Talc is known to be incompatible with quartenary ammonium compounds.38

Monobasic Calcium Phosphate
Monobasic calcium phosphate is used in the food industry as a leavening agent and in the
pharmaceutical industry for tablet production, due to its desirable flowability and good
compaction properties. The material is of anhydrous grade, white in color, granular and free
flowing. It is non-hygroscopic with true density of 2.23 g/cm3 and has poor water solubility
(18 g/l). Monobasic calcium phosphate is a considerably strong acid with a pH value of 2 for its
25% w/v slurry. The majority (95% w/w) of its particles pass through sieve of mesh size 90 µm.
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The acidic nature of the excipient limits its usage with drugs prone to acid catalyzed
degradation.38,39
Based on the above information, all excipients used in the presented research are likely to be
both physically and chemically stable under the accelerated study conditions employed. Most of
the excipients are also not likely to absorb large quantities of water under the low humidity
conditions (5%) of the study. Thus the confounding effect of moisture on gabapentin’s stability
during the accelerated storage period is less likely.

1.3.4. Models and Complexities in Solid-State Kinetics
The kinetic model for gabapentin reported in the literature included critical mechanisms such as
nucleation of lactam molecules in gabapentin crystals and autocatalysis of the conversion of
stable gabapentin molecules to reactive gabapentin molecules. The kinetic model designed to
predict solid-state stability of gabapentin has a combination of nucleation model theory and
Prout-Tompkins autocatalytic theory. Therefore it is important to understand the mechanisms
and principles underlying the existing solid-state models reported in the literature.

Solid-state kinetics differs from a typical solution state reaction due to the inhomogeneity
associated with the solid sample. The reactivity is different across different regions in the solid,
depending on the molecular degrees of freedom across the solid sample. In solids, reactions are
typically initiated at defect sites in the crystal lattice or at crystal surfaces, edges and corners.
Ideally, a perfect crystal has minimal reactivity due to the absence of any imperfections.
However, perfect crystals are rare and most crystal lattices contain imperfections. The lattice
imperfections are predominantly in the form of point defects and dislocations. The imperfection
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sites are energized sites due to molecules possessing higher free energy, resulting in lower
activation energy required to initiate and drive the reaction.40

A kinetic model is a theoretical and/or a mathematical description of a kinetic event that occurs
experimentally. In solid-state, a model can describe a particular reaction type and translate that
mathematically into a rate equation. Based on the mechanistic assumptions of the model and the
shape of the isothermal plot of concentration vs. time, they can be classified as sigmoidal,
acceleratory, linear or deceleratory.40, 41

Nucleation Model Theory: The kinetics of many solid-state reactions are described by
nucleation models typically the Avrami model. The rate limiting step in the model is assumed to
be the formation and growth of nuclei, which are finite quantities of products in the reactant
lattice. Nucleation models account for both nucleation and growth rates. However, the energy
barrier for nuclei generation would be larger relative to that for growth. The contribution of
nucleation may decrease as the reaction progresses, leading to an effective activation energy
that varies with the progress of the reaction. Nucleation rates are derived based on the
assumption that nucleation is either single step or involves multiple steps. Single step nucleation
assumes that nucleation and growth both take place in a single step, while in multi-step
nucleation, several steps are required to generate a growth nucleus.40,42-44 In the presented
research, the spontaneous conversion of reactive gabapentin to lactam is assumed to follow a
single step nucleation reaction.
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Reaction Order Based Model Theory: The rate law is based on the reaction order. These
models are simple models similar to those used in homogenous kinetics. In these models, the
reaction rate is proportional to the concentration, the amount or fraction, of remaining reactant
raised to a particular power. This is the reaction order.40-42, 45

Autocatalytic Model Theory: In homogenous kinetics, autocatalysis will occur when the
products catalyze the reaction. This occurs when the reactants are regenerated in the process
known as branching. In autocatalytic models, the reaction rate increases as the products are
formed. The reactants will be consumed over time and the reaction will enter the termination
stage where it will cease. The reaction rate vs. time profile shows a bell shaped plot with both
an acceleration and a decay period. The model was first derived by Prout and Tompkins for
thermal decomposition of potassium permanganate which produced considerable crystal
cracking during decomposition. The mechanistic model of nucleus branching was used to
formulate the Prout-Tompkins model.46-48 In the presented research, the generation of reactive
gabapentin molecules within a particle of gabapentin is expected to be autocatalyzed by the
concentration of lactam and inherent reactive molecules.

The Prout –Tompkins equation involves three assumptions:
1. Linear dependence of the termination rate constant (kT) on the concentration of the reactant
species. 2. If the first assumption holds valid then kT = kb/2ai where a = ai at inflection point on
the curve and kb is the branching rate constant. 3. Value of ai = 0.5 requires a sigmoidal curve
function. The derivative form of the Prout-Tompkins model is provided in Equation 7.
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𝒅𝒙
= 𝒌′ (𝟏 − 𝒙)(𝒙)
𝒅𝒕

Equation 7

In the above equation, x denotes the mole fraction of the product measured at time t, and k’
(mol-1h-1) is the rate constant for the transformation.46

Major complexities in solid-state kinetics of drug molecules
Solid-state kinetics typically involves major complexities, which need to be understood in order
to define the model assumptions. Some of the complexities relevant to the presented research
have been discussed below.

Distribution of reactive molecules: different samples of a material can possess different
concentrations of defect sites, defect types, and concentration of reactive molecules. Since the
above molecules are more reactive than ordered bulk molecules, they undergo a reaction at
different rates creating a complex kinetic scheme for drug degradation. This complexity exists
in the case of gabapentin’s degradation, wherein reactive molecules are likely to have different
rates of degradation and varying degrees of freedom. When describing degradation using a
kinetic scheme, it is important to describe it with simplicity in order to be able to accurately
estimate rate constants involved in the degradation. In the presented research, it is assumed that
no major differences are present between the degradation rates of disordered molecules due to
differences in their defect type (either on the surface or in the bulk of the crystal). In summary,
all the disordered molecules in the gabapentin crystal are assumed to have similar reactivity
irrespective of their defect type.
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Particle size variations in the sample: for reactions initiating at imperfection sites or crystal
surfaces, larger particles with lower specific surface area will likely have a lower overall rate of
degradation relative to smaller particles. Samples with variable particle sizes have a potential to
show complex reaction behavior. To eliminate the issue associated with varying particle size
distribution in the sample, gabapentin and the excipients selected for the presented research
were controlled for their particle size fractions.

Powder packing: sample packing could affect solid reaction kinetics, wherein loosely packed
powders, containing air pockets can have variable reaction kinetics compared to a tightly
packed sample. This is due to the reduced thermal conductivity of the air pockets in loose
powder or their ability to trap evolved gases.40,41 This could be one of the complexities
especially seen in the case of compacts of physical mixtures of gabapentin with the excipients.
The presented research, will explore the relationship between compact porosity of gabapentinexcipient physical mixture and the initial rate for lactam formation.

All the above complexities need to be considered when analyzing the kinetic data and selecting
a model for the solid-state drug degradation. Therefore understanding the mechanism of
degradation is critical when defining solid-state kinetics of drug molecules.

1.3.5. Solving Ordinary Differential Equation and Non-Linear Regression
On application of the desired model, the differential equations associated with the model need
to be numerically treated for approximation of a solution and estimation of the kinetic
parameters. The initial value problem for a differential equation involves finding a function y(t)
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that satisfies the initial condition y(t 0 ) = y0 A numerical solution based on equation 8
generates a sequence of values for every independent variable, t0, t1, ,….. tn, and a corresponding
sequence of values for the dependent variable y0, y1, ……, such that each yn approximates the
solution at tn.. Determination of step size (hn) is important when approximating a solution using
numerical methods (Equation 9).

𝒅𝒚
= 𝒇(𝒕, 𝒚(𝒕))
𝒅𝒕

Equation 8

𝒉𝒏 = 𝒕𝒏+𝟏 − 𝒕𝒏

Equation 9

The simplest numerical method for solution of an initial value problem is Euler’s method. It uses
a fixed step size h and generates an approximate solution by using Equation 10 and Equation 11
𝒚𝒏+𝟏 = 𝒚𝒏 + 𝒉𝒇(𝒕𝒏 , 𝒚𝒏 )

Equation 10

𝒕𝒏+𝟏 = 𝒕𝒏 + 𝒉

Equation 11

The biggest defect of the Euler’s method is that it does not provide an error estimate.
Single step methods are often called Runge-Kutta methods, after the two German
mathematicians. The classical Runge-Kutta was used for hand computations before the
invention of digital computers. It uses four function evaluations per step as shown in a series of
equations (Equation 12-16).49,50
𝒔𝟏 = 𝒇(𝒕𝒏 , 𝒚𝒏 )
𝒉
𝒉
𝒚𝒏 + 𝒔𝟏 )
𝟐
𝟐

Equation 13

𝒉
𝒉
𝒚𝒏 + 𝒔𝟐 )
𝟐
𝟐

Equation 14

𝒔𝟐 = 𝒇 (𝒕𝒏 +
𝒔𝟑 = 𝒇(𝒕𝒏 +

Equation 12
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𝒔𝟒 = 𝒇(𝒕𝒏 + 𝒉 𝒚𝒏 + 𝒉 𝒔𝟑 )
𝒚𝒏+𝟏 = 𝒚𝒏 +

Equation 15

𝒉
(𝒔 + 𝟐𝒔𝟐 + 𝟑𝒔𝟑 + 𝒔𝟒 )
𝟔 𝟏

Equation 16

After numerically estimating the solution to the differential equations using initial value
estimates for the parameters, the next step is to use non-linear regression to optimize parameter
estimations, which will provide a predicted curve that best fit the data.
Non-Linear Regression
A number of data sets are analyzed by fitting a curve using non-linear regression. Curve-fitting
standardizes data interpretation into a uniformly recognized form. Curve-fitting describes
experimental data as a mathematical equation in the form y = f(x), where x is the independent
variable and y is the dependent variable, and f is the function including the parameters that
describe the data.51

The non-linear regression is a powerful tool for fitting an equation to a set of data in order to
acquire values of unknown parameters. Similar to linear regression, non-linear regression
procedures determine parameter estimates by reducing the sum of squares of the distances of the
data points to the curve (least squares approach). If the ‘y’ value of each observed data point is
called ydata and the y predicted value of the curve is called ycurve, the goal is to minimize the
residual sum of squares (SS) as calculated in Equation 17. These methods are appropriate when
the experimental uncertainty is Gaussian and unrelated to the values of x and y.52

𝑺𝑺 = 𝒔𝒖𝒎 [(ydata – ycurve)2]

Equation 17
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The non-linear regression problems are solved iteratively. An initial estimate of the value for
each parameter is provided; the non-linear regression procedure then adjusts these values to
improve the fit of the curve to the data. The iterations (value adjustments) continue until
negligible improvement of the fit is observed. All iterative techniques are given a starting point
or initial estimate of parameter values by calculation or intelligent guessing. Several methods can
be chosen to perform the iterations. One of the commonly used techniques is the Marquardt
method. This method involves a combination of two algorithms namely, the method of steepest
descent and Gauss-Newton.52

The method of steepest descent works by providing an arbitrary step length to move along the
direction of steepest descent. This procedure is then repeated until the lowest value for the sum
of squares is obtained. Essentially, a minimum sum of squares is obtained by moving downhill
from the initial estimates provided for the parameters.52

The Gauss-Newton algorithm alters the value of parameters to directly reach the minimum The
Gauss-Newton method works poorly with initial iterations, and may result in a poor fit or a
wrong solution. This method works well when the sum of square error (SSE) is close to the
minimum.

Another iterative method is the simplex method, where the values for the initial estimate and the
initial increment value for each parameter needs to be provided. This method starts with three
starting values, and after several iterations the algorithm rejects the worst of the solutions
generated. The advantages of this method over other non-linear regression algorithms include its
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fast speed and its rare convergence to a local minimum. Hence, it can be used with noncontinuous functions. The disadvantages are that it does not estimate standard error for each
parameter and is more difficult to use since the starting increments for each parameter need to be
provided.52,53

The Marquardt method has several advantages, the most important being that it combines the
strengths of the methods, steepest descent and Gauss-Newton. Due to these advantages it has
been used to optimize the rate constants in case of the presented studies with gabapentin.52

Non-linear regression cannot find the best curve through a set of data points but can optimize the
parameters in a specified equation that calculates ‘y’ as a function of ‘x’ and one or more
parameters. The function is selected to describe a hypothetical physical or molecular model. All
non-linear regression procedures calculate the derivative of ‘y’ with respect to all parameters.
Some programs require the derivatives to be determined and entered as an equation, while other
programs such as Excel Solver® (used in this research), and calculate the derivatives numerically
by evaluating the equations before and after altering the value of the parameter by a small
amount. Initial estimates for each parameter in the equation need to be specified based on
previous experience, preliminary analysis based on linear transformation, or on a hunch. It is not
difficult to estimate parameters if one understands both the physical model that the equation
represents and the meaning of each parameter. Poor selection of initial values results in longer
processing times and may lead to the program going in a wrong direction and not converging to a
solution. It is also possible that poorly selected values can cause the program to converge on a
wrong solution.52
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Another important parameter in non-linear regression is the convergence criterion, especially
when calculations occur iteratively and the computer needs to be told when to stop. Too loose a
criterion can cause the program to stop before it has reached the best fit. On the other hand too
tight a criterion can result in consumption of the computer time. Considering the time limitation,
a tight convergence criterion (10-10) was attempted across all the parameter estimates for
gabapentin’s degradation in order to avoid convergence to a wrong solution.52,54

When assessing goodness of fit, it is important to examine the graph of the curve superimposed
to the data points. In addition to viewing the graph, two statistical methods can be used to
quantitate goodness of fit:
1. Root mean square (RMS) this takes into account the average deviation of the curve from the
points. When considering the residuals plot (residual vs. ‘x’ value), the ‘y’ value of each point is
replaced by the distance of that point from the curve. The residual value should be randomly
distributed across the plot. If the equation is inappropriate, the residuals tend to cluster. This
indicates systematic deviations of the data points from the predictions of the curve.
2. The value of the square of correlation coefficient (R2) is important for non-linear regression
when represented as a fraction of the variance in the ‘y’ value, reduced by the curve.52,54

In non-linear regression, it is possible that the final fit is not the best possible fit. To guard
against this issue one can repeat non-linear regression several times using different starting
values, this provides a more intuitive grasp of the equations used.
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In research studies with gabapentin the initial starting values were altered randomly as well as
systematically using a central composite experiment design in a 4 (parameters) x 3 (levels)
matrix. The range for altering the starting values was selected to be two orders of magnitude
higher and lower than the parameter estimates published in previous studies with gabapentin.1

1.3.6. Compaction as a Processing Condition
One of the research studies presented in this document involved understanding the impact of
compression pressure and powder properties of excipients on solid-state degradation of
gabapentin. This study was designed to test the hypothesis that exposure of gabapentin to
compaction pressure will increase lattice defects in gabapentin crystal and reduce its particle
size resulting in an increase in the initial rate for lactam formation. To understand the impact of
compaction pressure and powder properties of excipients, it is important to understand the
theory behind tablet formation.55

A tablet is formed by reducing the volume of particles consolidated into a single body. This
process can be divided as a series of different phases. At the beginning, the volume starts to
reduce and the particles are arranged into a closer packing structure. At a certain point, the
packing properties and friction between particles will prevent any further particle
rearrangement. At this point, further reduction in volume will result in an elastic, viscoelastic or
plastic deformation of the particles. Additionally, fragmentation will result in generation of
smaller particles, which will also undergo deformation resulting in volume reduction. Amongst
the excipients used in the presented research, microcrystalline cellulose, HPC and HPMC
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undergo plastic deformation, while talc, Emcompress® and the drug gabapentin deform by
brittle fragmentation.56-67

The process of compaction will result in the particle surfaces being brought in close proximity
with each other, leading to formation of inter-particulate bonds. Predominant bonding
mechanisms include, mechanical interlocking between irregularly shaped particles, interparticulate attraction forces and creation of solid bridges due to melting of particles. The process
of compaction will therefore result in increased particle contact and reduced particle size, both
of which will affect the solid-state degradation of drugs.61,63-65,68

A number of factors affect deformation mechanism. One such factor is material crystallinity.
Amorphous materials undergo plastic deformation while most crystalline materials undergo
brittle fragmentation.69,70 Particle size and shape are amongst other important determinants of
deformation behavior. It has been observed that increasing the irregularity and roughness of
granules changes the compression behavior from plastic deformation towards that of particle
fragmentation and attrition.71,72

Addition of glidants such as talc to the formulation results in decreased surface roughness of the
drug particles by formation of a uniform coating of the glidant particle around the drug particle.
This reduces the frictional drag between particles. Glidants also act as physical barriers between
particles reducing the attractive forces between them and removing any surface adsorbed
moisture to improve their flow properties.73,74

32

Moisture absorbed by amorphous regions in the materials have a significant effect on physical
and mechanical properties of formulations such as flow, compression, hardness, surface energy,
die-wall friction and Young’s elastic modulus.75 Moisture is responsible for plasticization of the
material during the compression phase, thus affecting the bond formation processes.76,75,77 This
highlights the need to understand the relationship between moisture content of the excipients
and the rate of lactam formation in the compacts of gabapentin with excipients.

Analysis of Powder Compaction Data
Studying compaction mechanism for powders has become an important part in the development
of solid oral dosage forms. Measurements related to the compaction of powders are facilitated
by the availability of instrumented tablet presses, commonly known as compaction simulators.
These instruments help measure punch force, upper and lower punch displacement, axial and
radial load transmission and temperature changes.

The Heckel Equation is amongst the most popular methods used in pharmaceutical research to
determine the volume reduction mechanism during compression.59,71,78,79 It is based on the
assumption that powder compression follows first order kinetics, with the inter-particulate voids
as the reactant and the powder densification as the product. According to the Heckel
relationship, the degree of compact densification with increasing compaction pressure is directly
proportional to porosity (Equation 18).
𝒅𝝆𝒓
𝒅𝑷

Equation 18

= 𝒌𝜺

In the above equation, 𝜌𝑟 is the relative density at pressure P and 𝜀 is the porosity.
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The relative density is defined as a ratio of density of the compact at pressure P, to the density
of the compact at zero porosity (true density).

Equation 19 is used in the calculation of porosity for gabapentin-excipient compacts to
understand the effect of compact porosity on the initial rate for lactam formation.
𝑽𝒑 − 𝑽𝟎
𝜺=(
) = 𝟏 − 𝝆𝒓
𝑽𝑷

Equation 19

In the above equation, 𝑉𝑝 and 𝑉0 are the volume at any applied pressure and volume at
theoretical zero porosity respectively. Equation 18 and equation 19 can be used to derive
equation 20.
𝒅𝝆𝒓
= 𝒌(𝟏 − 𝝆𝒓 )
𝒅𝑷

Equation 20

The differential equation in equation 20 can be solved to generate equation 21.
𝒍𝒏 [

𝟏
] = 𝒌𝑷 + 𝑨
(𝟏 − 𝝆𝒓 )

Equation 21

The plot of equation 21 yields a graph with a linear portion having slope k and intercept A.
The reciprocal of k gives a material dependent constant known as yield pressure (𝑃𝑦 ), which is
inversely related to the ability of the material to deform plastically under pressure.79-81 The
intercept of the extrapolated linear region A is a function of the original compact volume.

The main utility of Heckel plots arises from their ability to identify predominant deformation
behavior of a material. The Heckel relationship is explored in the presented research to
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understand the predominant deformation mechanism of the excipients in the physical mixture
with gabapentin, and for establishing any connection of this material property with accelerated
lactam formation.

1.3.7. Conclusion
Gabapentin is used in the treatment of many neurological disorders with a major application
being in the treatment of epilepsy. Gabapentin has a potential to undergo intramolecular
cyclization to form its degradation product lactam. Lactam is 20-fold more toxic than
gabapentin and has been reported to cause seizures in animal models. The concentration of
lactam has been regulated to 0.4% by USP. A number of recalls worth millions of dollars have
been issued in the last couple of years (2010-2013) due to the exceedingly high lactam content
in gabapentin formulations.

Literature findings have indicated an effect of pH, salt concentration and excipients on the
solution state stability of gabapentin. In solid state gabapentin is known to undergo accelerated
degradation under accelerated temperature conditions and application of processing conditions
such as milling and lyophillization. One study has highlighted potential effect of excipient type
on its degradation kinetics.

The main objective of this project was to test for the effect of excipient properties on
gabapentin’s degradation profile. In order to test the role of excipients a robust and accurate
analytical method was developed and validated for the quantification of gabapentin and lactam.
The overlying objective was to develop a relationship between the rate constant for lactam
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formation and properties of excipients affecting the degradation kinetics. The final objective
was to identify the effect of compaction as a processing condition on gabapentin’s degradation
profile considering its commercial availability as a solid oral dosage form.
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Chapter 2
Optimization and Validation of the Analytical Method for Determination of
Gabapentin and Its Degradation Product Lactam

2.1. Introduction
The objective of this dissertation is to identify various factors related to formulation composition
and compaction, which affect the solid-state stability of gabapentin. An important step toward
fulfilment of this objective is the accurate quantification of gabapentin and lactam in their binary
mixtures and in their compacts with excipients. Thus, selecting an analytical method, optimizing
and validating the same as per established guidelines, are a key aspects of the project.

Literature studies indicate a number of analytical methods using different instrumental
techniques for the separation and quantification of gabapentin and lactam. When selecting a
method, it is important to note that gabapentin is a highly polar compound which is poorly
retained on most reverse-phase high performance liquid chromatography (RP-HPLC) columns.
On the other hand, its degradation product, lactam, is strongly retained on RP-HPLC columns.
Due to gabapentin’s poor column retention, most analytical methods involve extraction and
derivatization steps before quantitative determination.36 The quantification of gabapentin in
human plasma and serum has been reported using gas chromatography, capillary electrophoresis
and HPLC techniques.52, 82-86 Analytical techniques developed for bioanalysis of gabapentin also
include mass spectrometry in combination with gas or liquid chromatography.52,85,86
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An analytical method using HPLC instrumentation along with UV detection and without
derivatization has been developed for the successful determination of potency for gabapentin in
its marketed formulations.5,36 The separation is achieved using a cyano column with an isocratic
elution method. The cyano column is selected due to the higher retention time of gabapentin
relative to the retention time on other C18 columns for organic molecules. The other reason stated
for column selection has been to exploit the combination of hydrophilic and hydrophobic
interactions of the cyano groups with compounds possessing amine or amide functional groups,
which are found in both gabapentin and lactam. The method used a higher volume (95% v/v) of
the aqueous phase relative to the organic phase to increase the retention time (71 min) for lactam.
The buffered aqueous phase had a neutral pH (6-7), since low pH conditions resulted in poor
resolution between gabapentin and lactam in addition to poor stability of gabapentin.5,36

The above method offered several advantages. Thus, it was selected, optimized (to improve its
specificity), and validated as per ICHQ2A guidelines. Along with the method validation,
preliminary studies to test the interference of excipients and filter membrane on the extraction
efficiency of gabapentin and lactam were performed. The stability of gabapentin and lactam in
the mobile phase and in the sample solvent was studied to negate the effect of solution state
kinetics confounding the observed degradation of gabapentin in its solid-state.

2.2. Materials and Methods
2.2.1. Materials
Gabapentin was obtained from Hangzhou Starshine Pharmaceutical Co. Ltd. (Hangzhou, China).
Gabapentin reference standard was purchased from the United States Pharmacopeia (USP)
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(Rockville, Maryland). Lactam standards were purchased from USP for the validation studies
and Sigma-Aldrich (St. Louis, Missouri) for all other preliminary studies. The excipients used in
the study included calcium phosphate dibasic dihydrate (Emcompress®, E. Mendell. Co. Inc,
New York), monobasic calcium phosphate (V-90 grade, Innophos, New Jersey), dibasic calcium
phosphate anhydrous (A-Tab®, Innophos, New Jersey), tribasic calcium phosphate anhydrous
(Tri-Tab®, Innophos, New Jersey), modified corn starch (Uni-pureTM DW, National starch LLC,
New Jersey), hydroxypropyl cellulose (HPC, Klucel EF®, Ashland Inc., Kentucky),
hydroxypropyl methyl cellulose (HPMC, MethocelTM E50 Prem LV, Dow Chemical Co.,
Michigan) and talcum (Talc, Fisher Scientific, Massachusetts).

HPLC grade monobasic

potassium phosphate and dibasic potassium phosphate were purchased from Sigma-Aldrich (St.
Louis, Missouri) for mobile phase preparation. HPLC grade acetonitrile was purchased from
VWR International (Radnor, Pennsylvania). Deionized water filtered through a 0.45 micron filter
was obtained from an in-house Milli-Q water purification system (Millipore Corporation,
Billerica, Massachusetts). Nylon syringe filters (0.4 µm) for sample filtration and nylon filters
(0.2 µm) for mobile phase filtration were purchased from VWR International (Radnor,
Pennsylvania).

2.2.2. Instrumentation and chromatographic condition
The method used a reverse phase HPLC system (Waters® 2890 separation module) equipped
with an ultra-violet (UV) photodiode array detector. The column selected was a μ-Bondapack
cyano column (3.9 mm x 390 mm) (Waters Co. Op. Massachusetts).87 The mobile phase was
composed of 95 parts phosphate buffer pH 6.8-7.0 (10 mM KH2PO4/ 10 mM K2HPO4) and
5 parts of acetonitrile. The mobile phase pH was adjusted to 6.8 to ascertain maximal stability of
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gabapentin in solution. The mobile phase pH was measured using pH meter H12210 (Hanna
Instruments, Carrolton, Texas). The mobile phase was filtered using a nylon filter (0.2 µm) and
degassed 1 h prior to analysis. Flow rate of the mobile phase was adjusted at 1.0 ml/min and the
injection volume of 20 µl was selected. Detection of gabapentin and lactam was performed at a
single wavelength of 210 nm with the column maintained under ambient temperature conditions
(20-22°C).

2.2.3. Analytical Method Validation
The analytical method was validated for specificity, assay, linearity, range, accuracy, precision,
limit of detection, and limit of quantification. The protocol for all designed studies and the data
reporting was as per ICH Q2A guidelines.

Specificity
Specificity of the method was determined by analyzing all single components, namely
gabapentin (2 mg/ml), lactam (40 μg/ml), and excipients (2 mg/ml) such as Emcompress®, ATab®, Tri-Tab®, Mono-Tab, HPMC, HPC, starch and talc used in the stability studies. All
chromatograms were evaluated to confirm the absence of similar elution times for gabapentin,
lactam, or any other confounding peaks from the excipients to be used in the study subsequently.

Assay (Determination of Purity) for Bulk Gabapentin
Gabapentin stock solution I (5 mg/ml) was prepared using the USP reference standard for
gabapentin in deionized filtered water as a medium for standard preparation. For complete
solubilization of gabapentin, the standard solution was sonicated for a minute. The stock solution
I was then used to prepare calibration standards (n = 3) at 5 different concentration levels by
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using a serial dilution technique. The five concentrations ranged from 0.5 mg/ml to 5 mg/ml. The
calibration was repeated on 3 separate days to determine the inter-day precision. The calibration
standards were then used to determine the purity of the bulk gabapentin procured for the
degradation studies.

Another stock solution II (5 mg/ml) of gabapentin was prepared using bulk gabapentin, which
was diluted with filtered deionized water to prepare sample solutions (n = 6) of low (0.5 mg/ml),
medium (2 mg/ml) and high (5 mg/ml) concentrations. The purity of gabapentin was determined
based on the linear equation of the calibration curve for gabapentin using calibration standards.
The purity of bulk gabapentin is reported as average percent purity (n = 6) relative to the
reference standard and precision has also been reported as percent relative standard deviation
(% RSD) amongst the replicates and confidence interval (95%) (n = 6).

Linearity and Range
Standard calibration curves were prepared using six calibrators (3 concentrations x 2 inj.) for
gabapentin over a range of 0.4–10 mg/ml and six calibrators (3 concentrations x 2 inj.) for lactam
over a range of 8–240 µg/ml on three separate days. The data of peak area versus drug
concentration was treated by linear least square regression analysis. The standard curves were
evaluated for inter-day and intra-day linearity.

Preparation of Standard Solutions for Calibration
A gabapentin stock solution III (20 mg/ml) was prepared using bulk gabapentin. Calibration
standards were prepared at 6 different concentration levels ranging between 0.4 mg/ml and
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10 mg/ml. A concentration range was selected, keeping in mind the larger mass of gabapentin
(200 mg) to be used for the accelerated stability studies. A lactam stock solution I (5 mg/ml)
was prepared using the USP reference standard. Since lactam is the degradation product
measured, the ability to detect and quantitate smaller concentrations was important. Keeping this
in

mind, calibration

standards

were prepared

for

concentrations

ranging between

8 µg/ml-240 µg/ml.

A gabapentin stock solution IV (20 mg/ml) was used to prepare quality control solutions at low
(0.4 mg/ml), medium (4 mg/ml), and high (10 mg/ml) concentrations. Similarly, a lactam stock
solution II (5 mg/ml) was used to prepare quality control solutions at low (8 µg/ml), medium
(40 µg/ml) and high (240 µg/ml) concentrations.

All of the above quality control and calibration standards were prepared using filtered deionized
water as a diluting medium. The above solutions were prepared in triplicates, on three different
days as part of the method validation.

Accuracy and Precision
The accuracy and precision of three different concentrations of gabapentin and lactam were
determined in triplicates. The analysis was performed on quality control solutions across the
calibration range on three separate days. The method accuracy was established by evaluating the
amount of gabapentin and lactam in the quality control solutions using the calibration standards.
The accuracy results are expressed as percent recovery (n = 3) of gabapentin and lactam from the
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quality control solutions. Precision, both inter-day and intra-day, is expressed as
%RSD (n = 3) for peak areas of gabapentin and lactam.

Limit of Detection and Limit of Quantitation
Limit of detection (LOD) and limit of quantitation (LOQ) for gabapentin and lactam were
calculated based on standard deviation of response (𝜎) and slope (s) of the calibration curves.
LOD is calculated as 3.3× (𝜎/𝑠) and LOQ is calculated as 10× (𝜎/𝑠). The response (𝜎) is the
standard deviation of intercepts and (s) is the average value of slope from the linear regression
equation of the calibration curves (n = 3). The calibration curves were developed in the
concentration range of 0.4 mg/ml–10 mg/ml for gabapentin and 8 mg/ml and 240 mg/ml for
lactam.

2.2.4. Method Optimization
Effect of Filter Membrane
The possibility of drug-filter membrane (nylon) interaction was determined by studying the
recovery of gabapentin and lactam from solutions of known concentrations and volume (2.5 ml).
The protocol involved passing the solutions twice through the syringe filter of a known pore size
(0.45 µm).

Quality control solutions (n = 2) of gabapentin at low (0.5 mg/ml) and high (5 mg/ml)
concentrations, and thoseof lactam at low (8 µg/ml) and high (240 µg/ml) concentrations were
filtered twice using a nylon syringe filter (0.45 µm/ 25 mm). Both the filtrates (F1 and F2) were
quantified for the concentration of gabapentin and lactam. The data is reported as the average
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(n = 2) percent recovery of gabapentin and lactam and average precision (%RSD, n = 2) for the
recovery of gabapentin and lactam from the filtrates.

Effect of Excipients
The analytical method was used to determine the extraction efficiency for gabapentin and lactam
in the presence of excipients, namely, Emcompress®, HPMC, starch, talc, and HPC. These
excipients were used in the stability studies with gabapentin. Physical mixtures (n = 2) of
gabapentin and excipient in a 1:1 proportion were prepared manually. The extraction efficiency
of lactam was determined by spiking its known concentration (200 µg) in the physical mixture.
The solutions prepared in deionized filtered water were sonicated for 10 min, filtered using a
nylon syringe filter (0.45 µm) and analyzed for the concentrations of gabapentin and lactam.

2.2.5. Stability of gabapentin and lactam
The stability of the aqueous solutions of gabapentin and lactam in the medium (deionized filtered
water) for sample preparation and in the mobile phase was determined. Samples of gabapentin
(10 mg/ml) and lactam (160 µg/ml) were prepared in deionized filtered water and stored under
room temperature conditions (20-22°C) in the dark for 24 h. The samples were analyzed for the
recovery of lactam and gabapentin, as well as for identification of any new products generated.
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2.3. Results and Discussion
2.3.1. Analytical Method Validation
Specificity
The sample chromatogram for gabapentin (2 mg/ml) is shown in Figure 6 and that for lactam
(40 µg/ml) is shown in Figure 7. Retention time (n = 18) for gabapentin was 3.75 min
(±0.009 min) and that for lactam is 7.61 min (±0.056 min). The peaks of both gabapentin and
lactam were well separated from each other and could be analyzed accurately. The study to test
the matrix effect confirmed absence of any co-eluting peaks, related to the excipients, at the
retention times of lactam and gabapentin (appendix 1).
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Figure 6: Sample chromatogram for gabapentin (2 mg/ml). The retention time is 3.75 min
(±𝟎. 𝟎𝟎𝟗 𝐦𝐢𝐧, 𝐧 = 𝟏𝟖). The solvent front is seen eluting at 2.5 min.
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Figure 7: Sample chromatogram for lactam (40 µg/ml). The retention time is 7.61 min
(±𝟎. 𝟎𝟓𝟔 𝐦𝐢𝐧, 𝐧 = 𝟏𝟖).
Assay for Purity Determination of Bulk Gabapentin
Bulk gabapentin was evaluated for its purity relative to its reference standard (USP). This step
was initiated to approve the use of bulk gabapentin in subsequent stability studies and analytical
method validation. Results for the calibration curve using the gabapentin reference standard are
reported in Table 2 and depicted in Figure 8. The results showed good correlation (R2≥0.999)
between peak area and gabapentin concentration. The results for percent recovery and precision
among replicates are reported in Table 3. The results suggested bulk gabapentin to possess purity
comparable to that of the reference standard. The percent purity and precision
(% RSD) of bulk gabapentin was 97.64% and 2.42% at low concentration (0.5 mg/ml), 102.44%
and 0.75% at medium concentration (2 mg/ml), and 100.49% and 0.28% at high concentration
(5 mg/ml) respectively. Hence, for subsequent studies involving gabapentin, the use of bulk
gabapentin was considered appropriate.
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Table 2: Calibration curve data using the gabapentin reference standard (USP). The
calibration was performed as per ICH Q2A guidelines on three separate days.
Linearity and Range for Calibration Curves Using Gabapentin Reference Standard (USP)
Analytical Range
(mg/ml)
0.5-5
0.5-5
0.5-5

Standard Curve

Peak Area

validation Day 1
validation Day 2
validation Day 3

Calibrators

Slope

y-intercept

5
5
5

509910
504610
504710

20062
21739
26862

3
4
Concentration (mg/ml)

5

3000000

y = 5.0991E+05x + 2.0062E+04
R² = 9.9951E-01

2500000

y = 5.0461E+05x + 2.1739E+04
R² = 9.9984E-01

2000000

y = 5.0472E+05x + 2.6862E+04
R² = 9.9946E-01

R2
Value
0.9995
0.9998
0.9994

1500000
1000000
500000
0
0

1

2

6

Figure 8: Calibration curves for gabapentin reference standard (USP) solutions.
Calibration was performed as per ICH Q2A guidelines on three separate days. The
equations represent linear correlation of the peak area for gabapentin and its
concentration on the three days of calibration.
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Table 3: Purity of bulk gabapentin for the analysis performed at three different
concentrations.
Gabapentin Purity: Bulk Drug Substance n = 6 (3 Rep. x 2 inj.))
Solution Concentration
0.5 mg/ml
2 mg/ml
5 mg/ml
% Purity
97.64
102.44
100.49
%RSD (Precision)
2.42
0.75
0.28
Confidence Interval
2.48
0.81
0.29
(95%)

Linearity and Range
The linearity for standard calibration curves was established in the analytical range 0.4-10 mg/ml
for gabapentin and 8-240 µg/ml for lactam. The results for linearity are summarized in Table 4
for gabapentin and in Table 5 for lactam. The results indicate good correlation (R2≥0.999)
between peak area and concentration for gabapentin and lactam in the analytical range selected,
as seen in Figure 9 and Figure 10.
Table 4: Linearity of calibration curves for gabapentin. Calibration was performed as per
ICH Q2A guidelines on three separate days. Slope, intercept, and the correlation coefficient
for the peak area and concentration plot have been reported.

Standard Curve
Validation Day 1
Validation Day 2
Validation Day 3

Linearity of Calibration Curves for Gabapentin
Analytical Range
Calibrators Slope y-intercept
(mg/ml)
0.4-10
6
549805
790.12
0.4-10
6
539610
- 15428
0.4-10
6
549788
18649
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R2 Value
0.9995
0.9994
0.9999

6000000

y = 549805x + 790.12
R² = 0.9995

Peak Area

5000000

y = 539610x - 15428
R² = 0.9995

4000000

y = 549788x + 18649
R² = 1

3000000

Calibration day 1
calibration day 2

2000000

calibration day 3

1000000
0
0

2

4
6
8
Concentration (mg/ml)

10

12

Figure 9: Calibration curves for gabapentin (Method Validation). Calibration was
performed as per ICH Q2A guidelines on three separate days. The equations represent the
linear correlation between the peak area for gabapentin and its concentration on the three
days of calibration.

Table 5: Linearity of calibration curves for lactam. Calibration was performed as per ICH
Q2A guidelines on three separate days. Slope, intercept and the correlation coefficient for
the peak area and concentration plot have been reported.
Standard Curve
Validation Day 1
Validation Day 2
Validation Day 3

Linearity Data of Calibration Curves for Lactam
Analytical Range (mg/ml) Calibrators Slope y-intercept
8-240
6
10382
-326.55
8-240
6
10392
579.55
8-240
6
10577
1016.3
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R2 Value
0.9999
0.9999
0.9999

3000000

y = 10382x - 326.55
R² = 1

2500000

y = 10392x + 579.55
R² = 0.9999

Peak Area

2000000

y = 10577x + 1016.3
R² = 0.9999

1500000

Calibration day 1
Calibration day 2

1000000

Calibration day 3

500000
0
0

50

100

150

200

250

300

Concentration (µg/ml)

Figure 10: Calibration curves for lactam (Method Validation). Calibration was performed
as per ICH Q2A guidelines on three separate days. The equations represent linear
correlation between the peak area for gabapentin and its concentration on the three days of
calibration.

Accuracy and Precision
The results for the accuracy and precision of analytical quality control samples are summarized
in Table 6 and Table 7 for gabapentin and in Table 8 and Table 9 for lactam. Method accuracy
was recorded to be greater than 97% at all concentration levels on all three days for gabapentin.
Method accuracy was also seen to be greater than 98% at all concentration levels on all three
days for lactam. Method precision (n = 3), represented as %RSD was seen to be lower than 2.5%
for both gabapentin and lactam. Inter-day and intra-day precisions were recorded to be lower
than 2% RSD as well.
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Table 6:Determination of accuracy for the analytical method using gabapentin. The
method accuracy was determined at three separate concentration levels on three separate
days.
Gabapentin Accuracy: Drug Substance (% Recovery n = 3)
Solution Concentration
0.4 mg/ml
4 mg/ml
10 mg/ml
Validation Set 1
98.48
97.46
98.11
Validation Set 2
100.27
97.79
100.09
Validation Set 3
99.41
100.29
101.82
Table 7:Determination of precision for the analytical method using gabapentin. Method
precision was determined at three separate concentration levels on three separate days.
Gabapentin Precision: Drug Substance (%RSD n = 3)
Solution Concentration
0.4 mg/ml
4 mg/ml
10 mg/ml
Validation Set 1
0.39
1.29
1.68
Validation Set 2
0.26
0.07
1.64
Validation Set 3
2.2
0.15
0.51
Inter-day
0.9
1.57
1.85
Table 8:Determination of accuracy for the analytical method using lactam. Method
accuracy was determined at three separate concentration levels on three separate days.
Lactam Accuracy: Drug Substance (% Recovery n = 3)
Solution Concentration
8 µg/ml
40 µg/ml
160 µg/ml
Validation Set 1
99.02
99.31
99.95
Validation Set 2
99.05
100.05
99.74
Validation Set 3
101.63
99.36
98.23
Table 9:Determination of precision for the analytical method using lactam. Method
precision was determined at three separate concentration levels on three separate days.
Lactam Precision: Drug Substance (%RSD n = 3)
Solution Concentration
8 µg/ml
40 µg/ml
160 µg/ml
Validation Set 1
0.57
0.44
0.3
Validation Set 2
0.56
0.25
0.12
Validation Set 3
2.22
0.22
0.98
Inter-day
1.49
0.41
0.94
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Limit of Detection and Limit of Quantitation
The limit of detection and the limit of quantitation for gabapentin were 57 µg and 174 µg,
respectively, while the limit of detection and the limit of quantitation for lactam were 0.15 µg
and 0.47 µg, respectively. Greater sensitivity for the detection of lactam relative to gabapentin is
due to its higher ultraviolet absorptivity, which is known to be almost one order magnitude
greater than that for gabapentin.

2.3.2. Method Optimization
Effect of Filter Membrane
The propensity of gabapentin and lactam to adsorb on the surface of the filter membrane used in
the stability studies was tested. The results of the study are reported in Table 10. The results
suggested complete recovery (100% ±3% w/w) of both gabapentin and lactam at high as well as
low concentrations, for both the filtrates. The recovery for gabapentin at low concentration
(0.5 mg/ml) was 99.46% for the first filtrate and 97.93% for the second filtrate. At a higher
concentration (5 mg/ml) the recovery of gabapentin was 100.15% and 100.46% for the two
filtrates tested. In the case of lactam, the recovery at a low concentration (8 µg/ml) was 103.6%
and 103.3% for the two filtrates, and at a higher concentration (240 µg/ml) the recovery was
99.4% and 100.1% for the two filtrates. Precision (%RSD, n = 3) for the recovery of gabapentin
and lactam post-filtration was seen to be below 2%.
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Table 10: The effect of the filter membrane on the recovery of gabapentin and lactam. The
recovery was analyzed for solutions of gabapentin and lactam at two different
concentrations, passed through the filter twice.
Recovery of Compounds Post Filtration Using Syringe Filter (Nylon, 0.45 µm)
Compound Concentration / Filtrate
%Recovery (n = 3)
%RSD (n = 3)
Gabapentin
Low 0.5 mg/ml / F1
99.46
0.92
Low 0.5 mg/ml / F2
97.93
1.14
High 5 mg/ml / F1
100.15
0.22
High 5 mg/ml / F2
100.46
0.21
Compound Concentration / Filtrate
%Recovery (n = 2)
%RSD (n = 2)
Lactam
Low 8 µg/ml / F1
103.3
0.23
Low 8 µg/ml / F2
103.66
1.7
High 240 µg/ml / F1
99.4
0.26
High 240 µg/ml / F2
100.18
0.06
* F1 = First Filtrate, F2 = second Filtrate
Effect of Excipients
The results for the recovery of gabapentin and lactam in the presence of excipients are reported
in Table 11. The recovery was seen to be greater than 97% for both gabapentin and lactam in the
presence of most excipients. The precision (%RSD, n = 2) for the recovery was seen to be less
than 3%.

Table 11: Results for the recovery of gabapentin and lactam in the presence of excipients.
Physical mixtures of gabapentin and lactam with the excipients were analyzed to determine
the effect of excipients on the extraction of either gabapentin or lactam in solution.
Recovery of Compounds in the Presence of Excipients
Compound
Excipients
%Recovery (n = 2)
%RSD (n = 2)
Gabapentin Emcompress®
98.62
0.57
talc
97.99
0.6
HPMC
97.73
0.09
starch
97.54
2.23
Lactam
Emcompress®
99.22
0.88
talc
98.56
0.11
HPMC
105.24
1.02
starch
97.67
2.47
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2.3.3. Stability of Gabapentin and Lactam
Lactam was found to be stable in an aqueous medium and under ambient temperature (22°C) and
humidity (30% RH) conditions for 24 h. Complete recovery (100% w/w) was observed for
lactam, while greater than 99% w/w recovery was observed for gabapentin. A small peak for
lactam (2 µg/ml) was seen eluting post 24 h from the gabapentin solution (10 mg/ml) (Figure
11). The degradation rate of gabapentin to lactam in solution was analyzed to be as low as
0.0008% mole/h. The total time gabapentin would be maintained in its solution state before
analysis was controlled to be less than 2 h. The preparation of samples prior to analysis
confirmed minimal (<0.0016% mole) lactam formation in the gabapentin solution at the time of
analysis.

3.750

0.010
0.008

Gabapentin
Lactam

0.006

7.710

0.004

AU

0.002
0.000
-0.002
-0.004
-0.006
-0.008
-0.010
2.00

4.00

6.00

8.00

10.00

Minutes

Figure 11: Chromatogram depicting the stability of gabapentin in the solution. A small
peak of lactam is seen eluting from the gabapentin sample stored for 24 h in dark under
ambient temperature and humidity conditions. The degradation rate for gabapentin in
solution was calculated to be <0.0008% mol/h.

54

2.4. Conclusion
The gabapentin (bulk) procured for the dissertation work was determined to be of purity
comparable to its reference standard. The HPLC method was successfully validated for accuracy,
precision, linearity, specificity, LOD and LOQ for gabapentin and lactam as per ICH Q2A
guidelines.

The method demonstrated specificity for gabapentin and lactam in the presence of excipients,
mobile phase medium, and water. The filters and the excipients in the study did not affect the
recovery of either gabapentin or lactam. Lactam was found to be stable in the solution medium
and mobile phase throughout the study duration. On the other hand, gabapentin was found to
convert at a very low rate in the solution under controlled pH conditions.

The method was therefore, considered suitable for the assessment of the solid-state stability of
gabapentin and for quantifying its degradation product, lactam, in the presence of excipients.
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Chapter 3

Investigating the Effect of Excipients on the Solid-State Degradation of
Gabapentin

3.1.

Introduction

As discussed in chapter 1, the degradation of drug molecules is accelerated by the presence of
excipients. This effect is either due to the chemical interactions between excipients and drug
molecules or due to the physical properties of the excipients.2

Commercially available solid dosage forms of gabapentin include film-coated tablets and hardshelled capsules. Formulating a strong and non-friable solid dosage form of gabapentin requires
the addition of excipients to improve its poor compressibility and poor flow properties. Typical
excipients used in gabapentin formulations include tablet diluents such as dibasic calcium
phosphate, binders such as HPC and corn starch, film coating polymers such as HPMC, flow
enhancers such as talc and lubricants such as magnesium stearate.

An important aspect of this research is to provide evidence for the accelerating effect of
excipients on the solid-state degradation of unprocessed gabapentin. The identification of
excipient properties that contribute to this effect will be explored in the next chapter.
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3.2. Materials and Methods
3.2.1. Materials
The model drug gabapentin (Hangzhou Starshine Pharmaceutical Co. Ltd., Hangzhou, China,
Batch 0803023) was procured for the stability studies. The excipients to be used in the stability
studies were selected based on commercially used excipients in gabapentin formulations and
other commonly used tableting excipients. The excipients selected include calcium phosphate
dibasic dihydrate (Emcompress®, E. Mendell. Co. Inc, New York), monobasic calcium
phosphate anhydrous (Mono-Tab, V-90 grade, Innophos, New Jersey), dibasic calcium
phosphate anhydrous (A-Tab®, Innophos, New Jersey), tribasic calcium phosphate anhydrous
(Tri-Tab®, Innophos, New Jersey), modified corn starch (Uni-pureTM DW, National Starch LLC,
New Jersey), hydroxypropyl cellulose (HPC, Klucel EF®, Ashland Aqualon Functional
Ingredients., Delaware), hydroxypropyl methyl cellulose (HPMC, MethocelTM E50 Prem LV,
The Dow Chemical Co., Michigan) and talcum (Talc, Fisher Scientific, Massachusetts). All other
reagents and solvents procured for analytical quantitation were of HPLC grade.

3.2.2 Material Pretreatment
Specific sieve fractions of the drug and the excipients were obtained by sieve classification using
a set of standard sieves (Gilson Company, Inc.) and a sieve shaker (Performer III Model SS-3,
Gilson Company, Inc.). The fractions retained on the sieves were weighed at intervals ranging
from 20-25 min, until the measured weight change between sieving was less than 0.5% w/w.
Specific particle size fraction between 125-250 µm was used for gabapentin and excipients (such
as Emcompress®, Modified corn starch, HPC and HPMC). However, a different particle size
fraction (75-125 µm) of the phosphate salts, (such as Tri-Tab®, A-Tab® and monobasic calcium
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phosphate (Mono-Tab) was used, due to the limited quantity of the larger particle size fraction
( ≥125 µm) for Mono-Tab on sieving. Talc was used as supplied in all experimentation, due to
its smaller particle size (100% <75 µm), which precluded classification by sieving.

Gabapentin, due to its reportedly poor stability under low humidity conditions, was equilibrated
under controlled conditions of temperature (20°C ±2°C) and humidity (33% RH, magnesium
chloride) for one week prior to the study.5 However, to prevent any confounding effects of
moisture from the excipients, they were equilibrated under controlled conditions of high
temperature (50°C) and low humidity (5% RH, Drierite®) for at least one week prior to the
study.

3.2.3. Determination of Moisture Content
The moisture content (% w/w) of the excipients was determined using thermogravimetric
analysis (TGA Q-500, TA Instruments, Delaware). The materials (25-50 mg) were heated from
ambient temperatures (25-30°C) to 110°C and maintained isothermally until the observed change
in the sample weight was less than 0.2% w/w per minute. Average value and standard deviation
of two replicate measurements is reported.

3.2.4. Physical Mixture Preparation and Study Conditions
To understand the effect of excipients on gabapentin’s stability profile, binary mixtures (n = 3) of
gabapentin and excipients, namely, Emcompress®, A-Tab®, Tri-Tab®, HPMC, HPC, starch,
Mono-Tab, and talc were prepared in a 1:1 proportion by weight. Binary mixtures were prepared
manually using the geometric dilution technique with the help of a spatula.
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All of the physical mixtures were observed under an optical microscope (Model BX-51,
Olympus, Pennsylvania) to determine the role of excipient morphology, and size of the excipient
particle on their distribution around gabapentin particles. Samples (n = 4) from different areas of
the physical mixture were collected and observed under low magnification (4x). Morphology of
the individual components was observed under higher (10x) magnification using the microscope.

To understand the effect of the mixing procedure on gabapentin’s degradation, gabapentin
samples (n = 3), controlled for their particle size (125-250 µm) were analyzed for lactam
formation, with and without application of the mixing procedure (manual mixing in a geometric
proportion using a stainless steel spatula).

Previous research has indicated the stabilizing effect of environmental moisture on gabapentin’s
degradation profile. The possibility of a similar stabilizing effect due to excipient moisture
content cannot be refuted. Even though the excipients used in the study had low moisture content
(<3% w/w), ascertaining a negligible impact of the excipient moisture content on the degradation
of gabapentin was important. The study to determine the effect of excipient moisture was
performed using Mono-Tab, which inherently possessed low moisture content (0.01% w/w).
Mono-Tab was mixed with water to account for a total of 1% moisture. Physical mixtures of
gabapentin and Mono-Tab with variable moisture content (0.01% w/w and 1% w/w) were
prepared, stored under accelerated conditions of temperature and humidity (50°C, 5% RH) and
analyzed using the HPLC technique. The effect of excipient moisture on the kinetics degradation
kinetics of gabapentin was further studied using HPMC equilibrated under different relative
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humidity conditions (33% RH, 85% RH). The moisture content of the HPMC samples prior to
physical mixing was recorded using thermo-gravimetric analysis (TGA).

All of the degradation studies were performed in scintillation vials (20 ml) under accelerated
conditions of temperature (50°C) and humidity (5% RH) for the entire duration (697 h) of the
study. Samples (n = 3) were withdrawn periodically for quantitation of gabapentin and its
degradation product lactam. Deionized and filtered (0.45 µm) water was used to prepare the
sample solutions. The sample solutions were filtered using a 0.45 µm nylon syringe filter prior to
the HPLC analysis. Data is reported as mean lactam concentration (% mole) over time (h) and
error bars represent the confidence interval (95%) for three replicates at every time point.

The existing kinetic model1 (Figure 4, pg. 13 ) for solid-state degradation of gabapentin was used
to understand the effect of excipients on gabapentin’s degradation profile.1 The Runge - Kutta
4th order numerical approximation method was used to solve the series of differential equations
defining the kinetic model using Excel® (2010, Microsoft®, Redmond, Washington).1 Matlab®
(R-2013, MathWorks®, Natick, Massachusetts), with its ode45 function handle (based on the
Runge-Kutta algorithm), was used to validate the results of the numerical approximations
calculated on Microsoft Excel®.

The parameters of the differential equations (Equation 1-3, pg. 13), especially rate constants k1
(autocatalytic branching), k2 (spontaneous dehydration), k3 (branching termination), and gaba0*
(initial concentration of reactive gabapentin molecules) were optimized using the least square
approach by the Solver function (Excel Solver®, Microsoft Office® 2010). A generalized reduced
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gradient (GRG) method based on the Levenberg-Marquardt algorithm with a forward derivative
was selected, a convergence criterion was set at 10-10, and a maximum of 1000 iterations were
allowed when parameterizing the model. Constraints were established in order to obtain
physically meaningful parameter estimates. One major constraint applied did not allow the
values of k1 and k3 to be lower than 10-8 in order to prevent the estimation of zero valued
parameters.

A common issue encountered when optimizing parameters using non-linear regression is
ensuring that the solution obtained is not a local minimum. To confirm that a global solution was
reached, a central composite design of experiments (CCD) (Table 12) was used to generate a
systematic combination of initial values over a broad range. The range for input values was
established based on the reported literature parameter estimates (k1 = 7.10x10-5, k2 = 0.020, and
k3 = 3.60x10-5) under similar experimental conditions (50°C, 5% RH).

1

A total of 25 different

combinations of input values were used during the optimization process. Input values for the
parameters k1 and k3 were varied in the range 0.000001-0.0001 mol-1h-1, while the value of k2
was varied between 0.1-0.00001 h-1, and the value of gaba0* were varied between 0.1-5% mole
respectively.
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Table 12: Application of a central composite design (CCD) approach to generate different
systematic combinations of input parameter values. Range for the parameter values is
selected based on previously published estimates.
CCD Input Values for Parameter Optimization
gaba0*(%
-1 -1
-1
-1h-1
k1 (mol h )
k2 (h )
k3 (mol )
mole)
-6
-6
-6
1x10
0.1
1x10
1x10
-6
-6
-6
1x10
5
1x10
1x10
-6
-6
-4
1x10
0.1
1x10
1x10
-6
-6
1x10
5
1x10
1x10-4
0.1
0.1
1x10-6
1x10-6
0.1
5
1x10-6
1x10-6
-6
-4
0.1
0.1
1x10
1x10
-6
-4
0.1
5
1x10
1x10
-6
-4
-6
1x10
0.1
1x10
1x10
-6
-4
-6
1x10
5
1x10
1x10
-6
-4
-4
1x10
0.1
1x10
1x10
-6
-4
-4
1x10
5
1x10
1x10
-4
-6
0.1
0.1
1x10
1x10
-4
-6
0.1
5
1x10
1x10
-4
-4
0.1
0.1
1x10
1x10
-4
0.1
5
1x10
1x10-4
-6
-5
0.05
2.55
1x10
5x10
-4
-5
1x10
0.05
2.55
5x10
-6
-5
-5
1x10
2.55
5x10
5x10
-5
-5
0.1
2.55
5x10
5x10
0.05
2.55
5x10-5
1x10-6
-4
-5
0.05
1x10
2.55
5x10
-5
-5
0.05
0.1
5x10
5x10
-5
-5
0.05
5
5x10
5x10
-5
-5
0.05
2.55
5x10
5x10

k1,k3

Range

High
Low
Medium

1x10-4
1x10-6
5x10-5

k2
High
Low
Medium

Range
0.1
1x10-6
0.05

gaba0*
High
Low
Medium

Range
5
0.1
2.55

Uncertainty (standard error) for the estimated parameters was calculated using a macro
(Solveraid®, Robert De Levie, Washington DC) on Excel® (2010, Microsoft®), with the code
written in visual basic developer (VBA).88 Parameter uncertainties were calculated based on the
partial differentials and matrix inversion method.88 The approach for uncertainty estimation is
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based on an assumption that the uncertainties in data pairs (x, yexp) are found in the dependent
variable (yexp) and that the uncertainties follow a Gaussian distribution.88 Uncertainties in
parameter estimates were calculated using Equation 22 through Equation 24. In the equations
below, N is the number of data pairs, P is the number of estimated parameters, and 𝑚𝑖𝑖 −1 denotes
the ith diagonal term of the inverse of a P × P matrix, the partial differentials of the fitting
𝑑𝐹

function 𝑑𝑎𝑛 ,where, 𝐹𝑛 = 𝑦𝑐𝑎𝑙𝑐 and 𝑎 is denoting the parameter to be estimated.
𝑖

𝒎𝒊𝒊
𝝈𝒊 = √

𝑵−𝑷
𝒅𝑭

𝒏
𝒎𝒊𝒋 = ∑𝑵
𝒏=𝟏 𝒅𝒂 ×
𝒊

𝒅𝑭𝒏
𝒅𝒂𝒊

Equation 22

𝟐
−𝟏 ×(𝒚
𝒆𝒙𝒑 −𝒚𝒄𝒂𝒍𝒄 )

𝒅𝑭𝒏

Equation 23

𝒅𝒂𝒋

𝒅𝑭

= 𝐥𝐢𝐦∆𝒂𝒊 →𝟎 𝒅𝒂𝒏 =

𝑭𝒏 (𝒙𝒏 𝒂𝒊 (𝟏+𝜹),𝒅𝒋≠𝒊 )−𝑭𝒏 (𝒙𝒏 𝒂𝒊 ,𝒅𝒋≠𝒊 )

𝒊

𝒂𝒊 (𝟏+𝜹)− 𝒂𝒊

,𝜹 ≪ 𝟏

Equation 24

3.3. Results and Discussion
The moisture content (% w/w) of the excipients equilibrated under low humidity (5% RH)
conditions is reported in Table 13. The moisture content of the excipients was recorded to be less
than 1% w/w in most cases except starch, which had a moisture content value of
2.69 ±0.28% w/w and HPC with a moisture content value of 1.97 ±0.38% w/w. The relatively
higher moisture content of the two excipients is due to their inherently high water absorption
capacities.
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Table 13: Mean moisture content (±Standard Deviation) of the excipients before physical
mixing.
No.
Excipient
Moisture Content (% w/w) (n = 2)
1
Mono-Tab
0.01 ±0.0007
2

talc

0.04 ±0.0007

3

Emcompress®

0.22 ±0.0141

4

A-Tab®

0.25 ±0.0353

5

HPMC

0.44 ±0.2899

6

Tri-Tab®

0.95 ±0.1272

7

HPC

1.97 ±0.3818

8

starch

2.69 ±0.2828

Optical images of the physical mixtures helped identify the effect of excipient particle size on the
distribution of excipient particles around the gabapentin particles. Images of the single
component particles (13A-20A) helped in their identification in the binary mixture. Optical
images for the physical mixtures of gabapentin and the excipients controlled for their particle
size (125-250 µm) are visualized in Figures 13B-16B. In the case of physical mixtures of
gabapentin with excipients of smaller particle size (75-125 µm) (Figure 18B-20B), a greater
number of excipient particles relative to gabapentin particles were observed. This observation
indicated, greater number of contact points between gabapentin and the excipient relative to the
contact points between gabapentin and larger sized excipient particles. In the case of talc
particles (Figure 17B) with the lowest particle size (<3 µm) amongst the excipients, the
adherence of fine talc particles on the surface of gabapentin was seen, indicating a likelihood of
greater surface contact between the two components. These observations suggested a need to
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account for the particle size of gabapentin and the excipients when understanding the effect of
the excipients on the degradation of gabapentin.

Figure 12: Image representing the morphology of a gabapentin particle under 10x
magnification.

A

B

Figure 13: Images representing the morphology of A. starch particles under 10x
magnification, and B. the physical mixture of gabapentin and starch particles under 4x
magnification.

A

B

Figure 14: Images representing the morphology of A. HPMC particles under 10x
magnification, and B. the physical mixture of gabapentin and HPMC particles under 4x
magnification.
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B

A

Figure 15: Images representing the morphology of A. Emcompress® particles under 10x
magnification, and B. the physical mixture of gabapentin and Emcompress® particles
under 4x magnification.

A

B

Figure 16: Images representing the morphology of A. HPC particles under 4x
magnification, and B. the physical mixture of gabapentin and HPC particles under 4x
magnification.

A

B

Figure 17: Images representing the morphology of A. talc particles under 500x
magnification, and B. the physical mixture of gabapentin and talc particles under 4x
magnification. The adherence of fine talc particles on the surface of rectangular gabapentin
particles is observed.
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A

B

Figure 18: Images representing the morphology of Mono-Tab particles under 10x
magnification, and B. the physical mixture of gabapentin and Mono-Tab particles under 4x
magnification.

A

B

Figure 19: Images representing the morphology of A-Tab® particles under 10x
magnification, and B. the physical mixture of gabapentin and A-Tab® particles under 4x
magnification.

A

B

Figure 20: Images representing the morphology of Tri-Tab® particles under 10x
magnification, and B. the physical mixture of gabapentin and Tri-Tab® particles under 4x
magnifications.
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The results of the study to test the effect of excipients on gabapentin’s degradation strongly
suggested a role of the excipients on solid-state degradation of gabapentin, as seen in Figures 21
and 22. A significant (95% confidence interval, n = 3) increase in lactam formation over the
entire study duration can be seen in the physical mixtures of gabapentin with each of the
excipients relative to lactam formation in their absence. Two different shapes for the lactam
formation profile were observed, which varied with the type of excipient used. Amongst the
physical mixtures, the gabapentin-Tri-Tab® mixture demonstrated the highest lactam formation
at 697 h, followed in relative order by the mixtures of gabapentin with A-Tab®, starch, MonoTab, Emcompress®, Talc, HPC, and HPMC. However, it is important to note the shape of each
degradation profile. It can be seen in Figure 21, that binary mixtures of gabapentin with
excipients Tri-Tab®, A-Tab®, Emcompress®, talc, HPMC, and HPC have a similar degradation
profile. In these profiles, a significant increase in the initial rate of lactam formation (<192 h) is
observed relative to the degradation profile for gabapentin. However, no distinct rise in lactam
concentration over time, representative of the branching/ termination phase was seen. The other
profile for lactam formation is shown in Figure 22, observed for gabapentin and the physical
mixtures of gabapentin with Mono-Tab and starch. These lactam formation profiles
demonstrated a lower initial rate of lactam formation relative to other excipients in the study.
However, a distinct branching phase is seen in their degradation profiles.
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Figure 21: Effect of the excipients on the solid-state degradation of gabapentin I. Mean
lactam formation (% mole) across time (h) for gabapentin excipient physical mixtures.
Degradation profiles represent significant (95% C.I., n = 3) an accelerated lactam
formation in the presence of excipients relative to gabapentin. Curves represent accelerated
initial rate of lactam formation (<192 h) but the absence of a distinct branching phase in
the degradation kinetics.
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Figure 22: Effect of the excipients on the solid-state degradation of gabapentin II. Mean
lactam formation (% mole) across time (h) for the gabapentin excipient physical mixtures.
Degradation profiles represent significant (95% C.I., n = 3) accelerated lactam formation
in the presence of excipients relative to gabapentin. The excipients did not affect the initial
rate of lactam (<192 h) formation as much as the other excipients in Figure 21. The
degradation profile clearly showed a distinct branching phase (>200 h) in the degradation
kinetics.
To attribute the observed accelerated lactam formation solely to the presence of the excipients, it
was important to negate the role of the mixing procedure on gabapentin’s degradation. This
experiment was performed to see if the mechanical shear experienced by gabapentin was not a
major contributor to the accelerated lactam formation. The results as seen in Figure 23,
demonstrate no significant (95% confidence interval, n = 3) change in the rate of lactam
formation across all time points for the gabapentin samples on application of the mixing
procedure.
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Figure 23: Effect of the mixing procedure on the solid-state degradation of gabapentin. The
mean lactam concentration (% mole, n = 3) over time (h) for samples of unprocessed
gabapentin in the presence and absence of simple mixing protocol. The error bars
represent a 95% confidence interval. No significant difference between lactam formation
across all time points is observed on the application of the mixing procedure.
Another factor that needed investigation, before attributing the observed accelerated lactam
formation to the presence of the excipients, was the moisture content of the excipient. The results
as seen in Figure 24, demonstrate no significant difference (95% confidence interval, n = 3) in
lactam formation until 697 h for the physical mixtures of gabapentin and Mono-Tab with
variable moisture content (0.01% w/w and 1% w/w). A moisture content of 1% w/w in the case
of Mono-Tab was selected to match the moisture content (0.95% w/w) of Tri-Tab® since TriTab® was the inorganic excipient demonstrating the highest effect amongst the excipients on the
rate of lactam formation. The moisture-induced stabilization of gabapentin molecules was not
observed in the case of the mixtures of gabapentin with Mono-Tab since the physical mixture
with the higher moisture content showed greater lactam formation. However, to confirm absence
of an accelerating effect on lactam formation as seen at 697h in Figure 24, further investigation
(collection of stability data points between 296-697 h) will have to be performed in case of
Mono-Tab.
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Figure 24: Effect of varying moisture content in Mono-Tab on the solid-state degradation
of gabapentin. The mean lactam concentration (% mole, n = 3) over time (h) for samples of
the gabapentin-Mono-Tab physical mixtures with variable moisture content. The error
bars represent a 95% confidence interval.
In the second study with HPMC, despite variable moisture content (6.66% w/w and
2.21% w/w) in the HPMC samples, no significant (95% confidence interval, n = 3) difference
between the degradation profiles of gabapentin and HPMC with variable moisture content was
observed (Figure 25). This finding negated the role of excipient moisture in accelerating the
degradation kinetics, which was thought to be a possibility in the case of the gabapentin-MonoTab physical mixtures as discussed above.
The results from the above studies confirmed the absence of a stabilizing effect of excipient
moisture on the degradation kinetics of gabapentin, especially in case of HPMC and Mono-Tab.
Based on the above results, the likelihood of excipient moisture content affecting the degradation
kinetics of unprocessed gabapentin seems less likely.
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Figure 25: The effect of varying moisture content in HPMC on the solid-state degradation
of gabapentin. The mean lactam concentration (% mole, n = 3) over time (h) for samples of
the gabapentin-HPMC physical mixtures. HPMC, possessed variable moisture content of
6.66% w/w at 85% RH and 2.21% w/w at 33% RH. The error bars represent a 95%
confidence interval.
Application of the Kinetic Model to the Observed Lactam Profiles
To apply the existing kinetic model to the data and estimate rate constants, the first step involved
development of an Excel® worksheet to solve the series of differential equations using the
Runge-Kutta approximation. The Excel® worksheet developed was successfully validated using
the ode45 function handle on MATLAB®. A comparison of the observed data with the predicted
degradation profile approximated by the MATLAB® routine and the Excel® spreadsheet can be
seen in Figure 26.
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Figure 26: Comparison of approximated lactam content (% mole) using the Runge-Kutta
method on Excel® and Matlab® routine relative to the observed lactam content (% mole)
over time for the gabapentin-excipient compact stored under accelerated temperature (50
°C) and humidity conditions (5% RH).
The next step involved use of the Solver function in Excel® to optimize rate constants and initial
concentration of reactive molecules (gaba0*), describing the degradation kinetics of gabapentin.
First optimization of the rate constants was performed on the data for unprocessed gabapentin by
fixing a lower value of gaba0*. The value of gaba0* was selected to be ~0.027 which was
substantially lower than the value (0.46% mole) of gaba0* published previously1 (by a separate
research group) for milled (15 min using ball mill at speed 5) gabapentin samples in the absence
of excipients. The lower value (0.027% mole.) of gaba0* was selected than that published
previously since a greater concentration of reactive molecules in an unprocessed gabapentin
sample was less likely. The results as shown in Figure 27 and Table 14 for unprocessed
gabapentin (red unfilled squares)

demonstrate a good fit between the data predicted by the

model and the experimentally observed data. The optimized rate constant values for gabapentin
data were also similar to those published previously.1 However, when the same lower value of
gaba0* was fixed to estimate the rate constants in the case of gabapentin- Tri-Tab® mixture
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(Figure 27: navy blue triangles) the model-predicted curve failed to provide a reasonable fit
resulting in a high SSE value, as shown in Figure 27 (green dashed line). A poor fit was obtained
irrespective of altering all the other rate constants in the model. This observation is due to greater
initial lactam formation (>0.7% mole at 200h) in the case of the gabapentin-Tri-Tab® physical
mixture relative to gabapentin (>0.02% mole at 200 h). As per the assumptions of the kinetic
model, the initial lactam formation is described predominantly by rate constant k2 and the
concentration of gaba0*. Thus a noticeably higher concentration of lactam in the case of the
gabapentin-Tri-Tab® physical mixture suggests a higher concentration of gaba0* present
inherently in the gabapentin sample used for the degradation study.

When Excel® solver was allowed to optimize all of the rate constants and the value for gaba0* for
the gabapentin-Tri-Tab® mixture data, the optimized value for gaba0* was ~3% mole. The
predicted lactam profile provided a good fit with the observed lactam concentration-time profile,
as seen in Figure 27 (navy blue dashed line). However, the estimated value of gaba0* was far
greater than that reported previously.

The next step was to ascertain if the higher value of gaba0* was able to predict the lactam
concentration for the gabapentin data published in the literature. Based on the published
literature values of the rate constants (Equations 4-6), a concentration-time profile for lactam
formation was generated (simulated) as seen in Figure 28 and Table 15. The estimated value for
the rate constants and higher value of gaba0* were used to generate a lactam formation profile as
seen in Table 15 and Figure 28. Despite a higher value of gaba0*, the predicted profile closely
matched the simulated lactam profile with a low (0.00009) SSE value. However, it is important
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to note the value of k2 in Table 15 changed significantly with the change in the value of gaba0*.
This observation is due to the correlation of the two parameters defining the initial rate of lactam
formation, as seen in Equation 3.
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Figure 27: Optimization of the parameters in gabapentin and the gabapentin-Tri-Tab®
physical mixture. The observed lactam concentration-time profiles for gabapentin (red
squares) and the gabapentin-Tri-Tab® physical mixture (blue triangles) are compared to
the model-predicted lactam profiles represented by dashed lines. The dashed line for the
gabapentin-Tri-Tab® model predicted data demonstrates the model predictions at higher
(blue lines) and lower value (green lines) of gaba0* respectively.
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Table 14: The model estimated parameters for the gabapentin and gabapentin-Tri-Tab®
physical mixture. A poor curve fit of model-predicted data is observed for the gabapentinTri-Tab® physical mixture after fixing for lower values of gaba0*.
Tri-Tab®
Fixing gaba0* at 0.027 and
Optimizing Other
Parameters

Tri-Tab®
Model
Estimated
Data

k1 (mol-1h-1)

Gabapentin
Fixing gaba0* at
0.027 and
Optimizing Other
Parameters
6.8x10-5

5.9x10-5

1.4x10-6

k2 (h-1)

2.5x10-4

0.64

1.5x10-3

k3 (mol-1h-1)

1.0x10-12

1.0x10-8

1.0x10-8

gaba0*(% mole)

0.027

0.027

3.000

SSE

3.80x10-6

3.39

3.60x10-3

Parameter

0.3
Simulated data using previously published
parameter estimates

% lactam mole
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Figure 28: Comparison of simulated and predicted lactam concentration-time profiles for
gabapentin, stored under accelerated temperature (50°C) and humidity (5% RH)
conditions. The simulated lactam profile is generated using the literature-reported rate
constants for gabapentin.1 The predicted lactam profile is generated using new parameter
estimates with estimated gaba0* greater than that reported previously.
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Table 15: The model-estimated parameter values for unprocessed gabapentin relative to
the previously estimated model parameters. No major alteration in the curve fit was
observed post-application of new parameter estimates with a greater value of gaba0*.
Parameter

Simulated Data
with Previously Published
Parameter Estimates1

Predicted data
With New Parameter Estimates

k1

6.0x10-5

7.5x10-5

k2

1.5x10-2

5.1x10-5

k3

7.6x10-5

3.8x10-5

gaba0*

0.027

3.30

SSE

NA

9.0x10-5

To confirm that a true solution was obtained after parameterization of the gabapentin-Tri-Tab®
data, non-linear regression was performed using 25 different sets of input values. The parameter
optimization resulted in an estimate of gaba0* that was 3% mole.

A clear increase in the sum of square error value and a poor fit of the model-predicted data was
observed when the value of gaba0* was fixed below 3% mole in the gabapentin-Tri-Tab® data. A
poor fit was obtained even after the alteration of other parameters, as seen in table 16.

Gaba0* was redefined as the combination of surface molecules and disordered molecules in the
bulk of the gabapentin crystal. Based on the results obtained for the gabapentin-Tri-Tab® data,
constraint on the value of gaba0* was set up to not be less than 3% mole. This constraint was
established when assessing profiles for other gabapentin-excipient mixtures since, in
unprocessed binary mixtures of gabapentin concentration of gaba0* was not expected to change.
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The change in the concentration of gaba0* is not expected since it represents the inherently
present reactive molecules in the gabapentin sample used in the study.
Table 16:Parameter estimates for the gabapentin-Tri-Tab® physical mixture, post-fixing
for different values of gaba0*.The table demonstrates an increase in the sum of square error
(SSE) value for the model-predicted fit after fixing for the value of gaba0* below 3% mole.
Parameter
k1
k2
k3
Fixed gaba0*
SSE

Input Value
1.4x10-6
0.0014
1.0x10-8
2.00
1.270

Optimized
Output Estimate
6.7x10-6
0.0022
1.0x10-8
2.00
0.009

k1
k2
k3
Fixed gaba0*
SSE

1.4x10-6
0.0014
1.0x10-8
1.50
4.480

9.0x10-6
0.0032
1.0x10-8
1.50
0.010

k1
k2
k3
Fixed gaba0*
SSE

1.4x10-6
0.0014
1.0x10-8
1.00
1.073

1.5x10-5
0.0050
1.0x10-8
1.00
0.045

k1
k2
k3
Fixed gaba0*
SSE

1.4x10-6
0.0014
1.0x10-8
0.5
6.818

2.2x10-5
0.0190
1.0x10-8
0.5
0.180

The kinetic model for the solid-state degradation of gabapentin was successfully applied to the
data and a good correlation between predicted and measured lactam concentration was observed,
with a low sum of square error (SSE <0.001) value across all gabapentin-excipient mixtures, as
seen in Table 16 and Figure 29. As can be seen from the Figure 29, a higher value (3% mole) of
gaba0* was able to provide good model fits to all of the gabapentin-excipient mixture data unlike
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a lower value (<2% mole) of gaba0*, which only fit a few gabapentin-excipient mixture profiles.
Thus the primary reason for a noticeable difference in the magnitude of the estimated value of
gaba0* between the previously published study1, and presented research could be due to the
initial development of the existing kinetic model only with processed gabapentin in the absence
of excipients. The model assumed no catalytic effect of the excipient on the rate constant k2. Rate
constant k2 and gaba0* are responsible for the rate of initial lactam formation, hence a change in
k2 value would impact the estimated value of gaba0* from that reported previously.
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Figure 29: A comparison between observed and model predicted lactam formation in
gabapentin and its physical mixture with excipients. Observed lactam concentration is
indicated by legends, while the dashed lines indicate model predicted fit. The error bars
represent a 95% confidence interval for three replicates across all time points. The above
data suggests a good fit between the data predicted by the model and the observed values of
lactam concentration.

80

After assessing the differential equations, (Equations 1-3), two parameters k2 and gaba0* seem to
be correlated. The correlation made it difficult to optimize the independent estimate values for
the two parameters with great precision. Thus, to increase certainty in estimation of rate constant
k2 the value for gaba0* was fixed at 3% mole and estimates for other rate constants were
obtained. Rate constants estimated for the data associated with gabapentin-excipient physical
mixtures is reported in Table 17. The table also provides values of SSE and coefficient of
determination (R2) between the observed and the model predicted lactam concentration values.
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Table 17: Summary of Optimized Rate Constants for the Degradation of Gabapentin with the Excipients

82

Constant

Tri-Tab®

A-Tab®

talc

Emcompress® HPC

HPMC

Mono-Tab

starch

no
excipient

k1

1.4x10-6
±9.7x10-8*

1.0x10-8
±1.2x10-7*

1.4x10-4
±1.7x10-7*

1.2x10-4
±9.5x10-7*

7.3x10-5
±1.5x10-6*

8.6x10-5
±7.4x10-6*

1.2x10-4
±3.1x10-5*

1.2x10-4
±1.3x10-5*

7.7x10-5
±4.5x10-4*

k2

1.4x10-3
±9.4x10-7*

1.3x10-3
±9.4x10-7*

1.0x10-3
±1.1x10-6*

3.5x10-4
±4.3x10-7*

2.2x10-4
±3.1x10-7*

1.1x10-4
±2.8x10-7*

6.9x10-5
±3.9x10-7*

6.5x10-5
±1.3x10-7*

7.2x10-6
±1.0x10-7*

k3

1.0x10-8
±1.4x10-7*

5.5x10-6
±1.8x10-7*

2.3x10-4
±3.0x10-7*

1.3x10-4
±1.0x10-6*

8.4x10-5
±1.6x10-6*

7.3x10-5
±7.6x10-6*

6.7x10-5
±3.2x10-5*

5.8x10-5
±1.3x10-5*

1.4x10-5
±4.5x10-4*

gaba0*

3

3

3

3

3

3

3

3

3

SSE

0.0036

0.0035

0.0005

0.0009

0.0004

0.0007

0.0108

0.0018

0.0005

R2

0.9990

0.9980

0.9980

0.9980

0.9920

0.9940

0.9920

0.9980

0.9680

* Estimated standard error using partial differentials and matrix inversion method

The presence of excipients in the physical mixtures with gabapentin resulted in an increased
value of the rate constant, k2 (h-1), as seen in Figure 30. The highest value for k2 (0.00149 h-1)
was obtained in the gabapentin-Tri-Tab® mixture, while the lowest value for k2 (6.39x10-5 h-1)
was obtained for starch. The magnitude of k2 in the absence of excipients was significantly lower
(7.20x10-6 h-1) than that in presence of excipients, strongly suggesting that excipients had a
catalytic effect on lactam formation.
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Figure 30: Estimated value for the rate constant k2 across the gabapentin-excipient physical
mixtures. Up to a 200-times increase in the value of the rate constant is observed for the
gabapentin-Tri-Tab® mixture relative to its value in the absence of excipients.

The rate constant k1, associated with autocatalytic branching, was estimated to be
7.75x10-5 mol-1h-1 in case of unprocessed gabapentin as seen in Figure 31. This estimate was
similar to the value of k1 (7.1x10-5 mol-1h-1) reported in the literature.1 In the presence of
excipients, the estimated value of the rate constant k1 was 8.45x10-5±0.000053 mol-1h-1.
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The value of the rate constant k3 which was responsible for reaction termination was
7.45x10-5±0.000073 mol-1h-1 across gabapentin and the gabapentin-excipient mixtures, as seen in
Figure 32.

Although the rate constants k1 and k3 did not change significantly in the presence of most
excipients, much lower values were estimated for the mixtures of gabapentin with Tri-Tab® and
A-Tab® (Figures 31 and 32). This effect was possibly due to the significantly higher magnitude
of the rate constant k2, which could be potentially masking the impact of the other two rate
constants (k1 and k3) in the degradation profiles of gabapentin with Tri-Tab® and A-Tab®.
Lactam profiles for Tri-Tab® and A-Tab® do not display the characteristic acceleration
associated with the autocatalytic branching phase defined by the current model (Figure 22). On
the other hand, the autocatalytic phase is seen distinctly in gabapentin and its physical mixtures
with starch and Mono-Tab, with lower estimated values of the rate constant k2. It is observed that
as the initial rate of lactam formation (<192 h) increases, branching phase starts to get less
prominent as seen in Figure 21, which possibly makes estimation of the rate constants k1 and k3
difficult.
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Figure 31: Estimated values for the rate constant k1 (mol-1h-1) across the gabapentinexcipient physical mixtures. The significantly lower value of k1 in the case of A-Tab® and
Tri-Tab®, is thought to be due to the higher magnitude of k2 masking the actual
branching/termination phase (described by k1) in the degradation kinetics of gabapentin.
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Figure 32: Estimated values for the rate constant k3 (mol-1h-1) from the lactam
concentration time profiles for the gabapentin-Excipient physical mixtures. The
significantly lower value of k3 in the case of A-Tab® and Tri-Tab®, is thought to be due to
higher magnitude of k2 masking the actual branching/termination phase (described by k3)
in the degradation kinetics of gabapentin.
.
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3.4. Conclusion
The major objective of this chapter was to provide evidence for the effect of excipients on the
solid-state degradation of gabapentin. The objective was accomplished, when clear impact of the
excipients on the solid-state degradation of gabapentin was confirmed in unprocessed powder
mixtures. The method for preparation of the powder mixtures and the initial excipient moisture
content were not found to affect the lactamization kinetics.

The central hypothesis of the research was that the physicochemical properties of the
excipients will accelerate the solid-state degradation of gabapentin, increasing the rate
constant for lactam formation (k2). The degradation kinetics, predominantly the initial rate
of lactam formation, will be further accelerated by compaction of the gabapentin-excipient
physical mixtures.

The results from this chapter proved the hypothesis that conversion of reactive gabapentin to
lactam driven by the rate constant k2 was affected greatly by the presence of excipients. The
magnitude of the rate constant k2 was almost 200-times higher in the case of the gabapentin-TriTab® physical mixture relative to its value for gabapentin. A possible reason for this effect could
be general base catalysis in solid-state catalyzed by basic materials like Tri-Tab®. However, the
subsequent chapter (Chapter 4) will focus on understanding the role of excipient properties
responsible for the increased value of rate constant (k2) catalyzed by the excipients. The Rate
constants k3 and k1, responsible for autocatalytic branching and the branching termination steps
in the kinetic scheme were less affected in the presence of most excipients.
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The value of gaba0* was estimated to be around 3% mole which included the surface molecules
and other disordered molecules in the gabapentin crystal. The estimated value was found to be
higher than that reported in the literature for the degradation of gabapentin. Further studies will
have to be carried out to confirm and justify the unexpectedly greater value of gaba0*.
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Chapter 4
Expansion of the Kinetic Model of Gabapentin Degradation to Account for
the Physicochemical Properties of Excipients

4.1. Introduction
In chapter 3, the accelerated degradation of unprocessed gabapentin in the presence of excipients
was studied. This chapter will focus on understanding the impact of excipient concentration, and
excipient particle size on the degradation of gabapentin.

The observation of accelerated degradation of gabapentin in the presence of excipients prompted
modification of the existing kinetic model to account for the presence of excipients. To expand
the model and incorporate the excipient effect, it was important to confirm the catalytic effect of
excipient concentration on degradation kinetics.

One of the critical aims of this chapter will be the expansion of the kinetic model to account for
the excipient effect. The aim is to establish a relationship between the physical properties of
excipients, such as particle size, particle shape, density, specific surface area and molecular cross
sectional area, with the rate constant for lactam formation.
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4.2. Materials and Methods
4.2.1. Materials
The materials used in the study are similar to those used in chapter three. However this chapter
mainly focuses on the impact of excipient (A-Tab®) mass and particle size on the degradation of
gabapentin. The physical properties of calcium phosphate dibasic dihydrate (Emcompress®, E.
Mendell. Co. Inc, New York), monobasic calcium phosphate (V-90 grade, Innophos, New
Jersey), dibasic calcium phosphate anhydrous (A-Tab®, Innophos, New Jersey), tribasic calcium
phosphate anhydrous (Tri-Tab®, Innophos, New Jersey), modified corn starch (Uni-pureTM DW,
National Starch LLC, New Jersey), hydroxypropyl cellulose (HPC, Klucel EF®, Ashland
Aqualon Functional Ingredients., Delaware), hydroxypropyl methyl cellulose (HPMC,
MethocelTM E50 Prem LV, The Dow Chemical Co., Michigan) and talcum (Talc, Fisher
Scientific, Massachusetts) were measured. All other reagents and solvents used for the analytical
quantitation were HPLC grade.

4.2.2. Study Designs
The particle size fractions of gabapentin and the excipients were obtained by sieve classification
using a set of standard sieves (Gilson Company, Inc.) and a sieve shaker (Performer III Model
SS-3, Gilson Company, Inc.) as described in chapter 3. The particle size fractions of A-Tab®
(75-125 µm, 125-250 µm, 250-500 µm) were separated to study the effect of surface contact
between gabapentin and the excipient on gabapentin’s degradation
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Gabapentin was maintained under controlled conditions of temperature (20°C ±2°C) and
humidity (33% RH, magnesium chloride) for a week prior to the studies due to its higher
stability under these conditions. The excipients were stored under controlled conditions of
temperature (50 °C) and humidity (5% RH, Drierite®) for at least one week prior to the study to
ensure a minimal confounding effect of excipient moisture content on gabapentin’s degradation.

To confirm the catalytic effect of excipient mass in the binary mixture, gabapentin was
physically mixed (n = 3) with different concentrations (5%, 20%, 35%, 50% w/w) of A-Tab®
controlled for their size (125-250 µm). Concentrations of excipient greater than 50% w/w were
not considered for the study since gabapentin is a low potency drug, commercially available as
tablets in a 600-800 mg dose. Hence, the concentration of excipients greater than 50% in a
gabapentin formulation is less likely.

Assuming the catalytic effect of the excipients follows the Law of Mass Action, the rate constant
for degradation should be proportional to the number of excipient molecules in contact with
gabapentin molecules. Accordingly, it was hypothesized that increasing the particle size of the
excipients would decrease the rate constant for lactam formation by decreasing the number of
surface molecules available for interaction. To test this hypothesis and understand the effect of
the contact area between gabapentin and excipient particles, physical mixtures of gabapentin and
different particle size fractions (75-125 µm, 125-250 µm and 250-500 µm) of A-Tab® were
prepared in a 1:1 proportion by weight.

90

All of the above physical mixtures were stored in scintillation vials (20 ml) under controlled
conditions of temperature (50 °C) and humidity (5% RH) for the entire study duration (697 h).
Samples (n = 3) of the mixtures were withdrawn periodically for quantitation of gabapentin and
its degradation product lactam. Deionized and filtered (0.45 µm sized filter) water was used to
prepare the samples. The samples were filtered using a 0.45 µm nylon syringe filter and analyzed
using a validated analytical method as discussed in chapter 2.

The existing kinetic model for solid-state degradation of gabapentin was applied to the generated
data.1 The Runge-Kutta 4th order numerical approximation method was used to solve the series
of differential equations (Equations 1-3) defining the kinetic model.1 The data collected was
further parameterized using non-linear regression by applying the least squares approach using
Excel® Solver (Excel® 2010). Constraints on the values of gaba0* and the rate constant k1 and k3
were set up as discussed in chapter 3. To understand the role of the physical properties of the
excipients on gabapentin’s degradation, a thorough characterization of the excipient’s physical
properties, such as particle size (µm), particle shape, true density (g/cm3), molecular cross2
̅̅̅
sectional area (𝐴𝑥 , m2), and specific surface area (𝑆
𝐸 , m /g), was performed.

4.2.3. Particle Size and Shape Determination
The varying morphology of gabapentin and the excipients required measurement of the mean
particle size (Feret diameter) using an optical microscope. Measuring the Feret diameter (cm)
was especially valuable for materials with a needle shaped or rectangular prismatic morphology.

91

Images of gabapentin and excipient particles (n >>200) were acquired using a light microscope
(Model BX-51, Olympus, Pennsylvania). The images were visualized under 10x objective for
most excipients and 50x objective in the case of talc. The images were processed using Image J
software (U.S. National Institutes of Health, Bethesda, Maryland, version 1.41o), to calculate the
mean Feret diameter.

An optical microscope was also used to visualize the particle morphology for all excipients and
measure the dimensions (length and breadth) of rectangular particles. Excipient particles
(n >>100) were analyzed using the Image J software, to determine particle circularity according
to Equation 25.
𝑪𝒊𝒓𝒄𝒖𝒍𝒂𝒓𝒊𝒕𝒚 = 𝟒𝝅 ×

𝑨𝒓𝒆𝒂 𝒐𝒇 𝒂 𝒑𝒂𝒓𝒕𝒊𝒄𝒍𝒆
𝑷𝒆𝒓𝒊𝒎𝒆𝒕𝒆𝒓 𝒐𝒇 𝒂 𝒑𝒂𝒓𝒕𝒊𝒄𝒍𝒆 𝟐

Equation 25

Circularity values typically range from 1 in the case of a perfect circle to 0 in the case of an
infinitely long polygon. The circularity values helped differentiate the morphology of the
different materials.

4.2.4. Determination of Molecular Cross-Sectional Area
To compute the cross-sectional area of the excipient molecule, the 2-dimensional (2-D) chemical
structure of each excipient was acquired using ChemDraw® software (version 13.0, PerkinElmer.
Massachusetts). In the case of polymers, the structures of the monomer units were considered for
the determination of the molecular cross-sectional area. The 2-dimentional chemical structure
was transformed to a 3-dimensional structure using Molecular Operating Environment (MOE
2013.08, Chemical Computing Group, Quebec, Canada) software. Energy minimization was
performed using force field MMF94X and a 0.05 gradient. The van der Waals radii of atoms
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were taken into account, and the contours of the projections were smoothened using a water
probe of 1.4 Å radius. The lengths of the major and minor axis of the projected surface in two
orientations were measured to compute the average cross-sectional area of the molecule
assuming an ellipsoidal geometry. The computed molecular surface and the axis measured for
the cross-sectional area determination are depicted in appendix 2.

4.2.5. Specific Surface Area Measurements
2
̅̅̅̅
One of the most important physical properties of a material is its specific surface area (𝑆
𝐸, , m /g).

This property becomes especially important when understanding interactions at the drugexcipient interface. The measurements of specific surface area were made using nitrogen vapor
adsorption data (FlowSorb II 2300, Micromeritics Instrument Corporation, Georgia) with
subsequent application of Brauner,Emmett and Teller (BET) model. Helium was employed as
the carrier gas and liquid nitrogen served as the external coolant. Approximately 1.0-1.5 g of the
excipient was filled into a clean, dry sample tube. The samples were outgassed for more than
24 h at higher temperatures (50-200°C) for calcium phosphates (anhydrous grade) and talc. To
prevent alteration of any physical properties, materials such as dibasic calcium phosphate
dihydrate, modified corn starch, HPC, and HPMC were outgassed at 50°C for more than 24 h
and further degassed at 50°C for 5 h. A single sample of each material was analyzed.
Measurements were conducted at a series of relative pressures (p/p0) of 0.05, 0.10, 0.15, 0.20,
0.25, and 0.30, and the moles of nitrogen adsorbed (n) at each of the partial pressures was
analyzed with the BET equation (Equation 26), given below in its linear form.
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𝑷
𝑷𝟎

𝑷
(𝒄 − 𝟏)
𝟏
𝑷𝟎
=
+
𝑷
𝒄 × 𝒏𝒎
𝒄 × 𝒏𝒎
𝒏(𝟏 − )
𝑷𝟎

Equation 26

Linear regression analysis was used to estimate the moles of nitrogen adsorbed at monolayer
coverage (nm) and the affinity constant (c). The specific surface area was taken as a quotient of
the sample’s total surface area and mass. The cross-sectional area of a nitrogen molecule was
assumed to be 16.2 Å2 in all of the calculations.

4.2.6. True Density Measurement
The true density of the materials was used to estimate the number of excipient and drug particles
in the mixture considering for their volume and mass. The measurements were also used to
estimate the solid fraction of gabapentin-excipient compacts, which will also be discussed in
chapter 5. This measurement uses helium pressure and Boyle’s law (the product of pressure and
volume is constant for a closed system at a fixed temperature) to calculate the volume occupied
by powder particles. The true density of each material weighing between 5-10 g was measured in
triplicates using helium pycnometry (Model: SPY-6DC, Quantachrome Instruments, Boynton
Beach, Florida). The samples were degassed for 30 min. To determine the effective powder
density, the volume was normalized by the final powder mass.

4.2.7. Theoretical Estimation of the Fraction Surface Area of the Excipient Particle in
Contact with Gabapentin Particle
In binary mixtures of gabapentin with excipients, it is expected that a single particle of
gabapentin will be in contact with multiple particles of excipients and gabapentin. To calculate
the fraction of excipient surface area in contact with gabapentin, the first step involved
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estimating the number-fraction of excipient particles and gabapentin particles around a single
gabapentin particle in the mixture.89,90 The Komatsu model89 was used for this purpose. This
model was developed for binary mixtures. It assumes as per Equation 27, the number ratio of the
individual component particles in the mixture (𝑁𝐴 and 𝑁𝐵 ) to be equal to the ratio of each
component particle ( 𝑛𝐴 𝑎𝑛𝑑 𝑛𝐵 ) contacting a single particle in the binary mixture (Equation
27).89,90
𝒏𝑨
𝑵𝑨
=
𝒏𝑩
𝑵𝑩

Equation 27

Assuming, a binary mixture of two components A and B, 𝑛𝐴 𝑎𝑛𝑑 𝑛𝐵 are the number of particles
of component A and B in contact with a single particle of component B.
The total number of individual component particles (𝑁𝐵 𝑎𝑛𝑑 𝑁𝐴 ) in the binary mixture is
estimated using the molar mass (𝑀𝑤), true density (𝜌) and volume (𝑉) of the individual
components (Equation 28).89,90
𝑵𝑨
𝑽𝑩 × 𝝆𝑩 × 𝑴𝒘𝑨
=
𝑵𝑩
𝑽𝑨 × 𝝆𝑨 × 𝑴𝒘𝑩

Equation 28

The Komatsu model was used to estimate the total number of individual component particles
(𝑁𝐵 𝑎𝑛𝑑 𝑁𝐴 ) and the number-fraction of component A (excipient) particles and component B
(gabapentin) particles around a single particle B (gabapentin) in the binary mixture
(Equation 29-30). 89,90 The volumes of the excipient and gabapentin particles were determined
based on the morphology, and the dimensions of the particles measured using optical
microscopy.
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𝒏𝑨
(𝒏𝑨 +𝒏𝑩 )
𝒏𝑩
(𝒏𝑨 +𝒏𝑩 )

=
=

𝑵𝑨
𝑵𝑩
𝑵
𝟏+ 𝑨
𝑵𝑩

Equation 29

𝟏

Equation 30

𝑵
𝟏+ 𝑨

𝑵𝑩

The next step involved the use of Equation 31 to estimate the total number of particles (𝑁𝑇 )
(excipient + gabapentin) contacting a single particle of gabapentin. This was calculated using the
surface area of the gabapentin particle and the contact surface area (CSA) between the excipient
and gabapentin particles.
𝑺𝒖𝒓𝒇𝒂𝒄𝒆 𝒂𝒓𝒆𝒂 𝒈𝒂𝒃𝒂𝒑𝒆𝒏𝒕𝒊𝒏 𝒑𝒂𝒓𝒕𝒊𝒄𝒍𝒆
𝑵𝑻 = 𝒏
𝒏
( 𝒏𝑨 × 𝑪𝑺𝑨 𝒆𝒙𝒄𝒊𝒑𝒊𝒆𝒏𝒕) + ( 𝒏𝑩 × 𝑪𝑺𝑨 𝒈𝒂𝒃𝒂𝒑𝒆𝒏𝒕𝒊𝒏)

A

A
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Figure 33: Graphical
representation of the physical mixture of gabapentin (rectangular
prismatic) particles
(B) with excipient particles (A) of different shapes, I. Spherical or
p
nearly spherical
i excipient particles. II. Rectangular prismatic excipient particles.
III. Contact area
e between particles of gabapentin and spherical excipients IV. Contact
area between particles of gabapentin and rectangular excipients
n
t
B
The surface area of the gabapentin particle was estimated by measuring its dimensions (length
=
and breadth) using optical microscopy. The height of the gabapentin particle was assumed to be
g
equal to its breadth
a considering the limitation of 3-D imaging on an optical microscope. The
b
cross-sectional areaa (CSA) of the excipient and gabapentin particles were calculated based on the
p
particle morphologies In the case of rectangular particles, two different orientations were
e
n
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possible; in these cases the mathematical average of the contact surface area for the two
orientations were used to estimate the total number of particles, as per Equation 31. In the case
of spherical excipient particles in contact with gabapentin, the point of contact would typically
be a point on the spherical surface contacting gabapentin (Figure 33, I). Since it is difficult to
measure the area of a point contact, the area of interaction (Van-der-Waals) between a sphere
and a plane (π x2) was calculated as the particle contact area. The distance x (Figure 33 III) was
measured using optical microscopy in conjunction with the image J software. The range for PCA
between the gabapentin and excipient particle with a rectangular prismatic morphology (Figure
33 II) was calculated using the formula for area of contact between two rectangular bodies
(length × breadth). The dimensions of excipient particles (rectangular prismatic) were also
measured using optical microscopy (Fig. 33 IV).63 After estimating 𝑁𝑇 as per Equation 31, the
number of excipient (𝑁𝐸 ) and gabapentin particle around a single gabapentin particle was
calculated using Equation 32.
𝑵𝑬 =

𝒏𝑨
× 𝑵𝑻
𝒏

Equation 32

Finally, the fraction surface area (𝒇) of the excipients in contact with gabapentin was calculated
using Equation 33. This equation helped in calculating the fraction surface area of the excipient
in contact with gabapentin, accounting for the effects of size, shape, and density of both the
gabapentin and excipient particles.
𝒇=

𝑵𝑬 × 𝑷𝑪𝑨 (𝒎𝟐 )
𝑺𝒖𝒓𝒇𝒂𝒄𝒆 𝒂𝒓𝒆𝒂 𝒐𝒇 𝒆𝒙𝒄𝒊𝒑𝒊𝒆𝒏𝒕 (𝒎𝟐 )

Equation 33
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4.3. Results and Discussion
The results in chapter 3, have demonstrated the impact of excipients on the solid-state
degradation of gabapentin. The results in Figure 34, strongly suggests an increase in lactam
formation with an increase in the concentration of the excipient (A-Tab®) in the binary mixture
with gabapentin. This observation supported the hypothesis that excipient molecules play a role
in the kinetics of gabapentin’s degradation in a concentration-dependent manner. Consequently,
the existing kinetic model needed modifications to account for the presence of excipients.

% lactam mole

1.6

A-Tab (0 % w/w)

1.4

A-Tab (5% w/w)

1.2

A-tab (20% w/w)
A-Tab (35% w/w)

1

A-Tab (50% w/w)

0.8
0.6
0.4
0.2
0
0

100
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Time (h)
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Figure 34: Effect of excipient concentration on the degradation of gabapentin. The graph
represents mean lactam concentration (% mole) over time (h) with increasing
concentration of the A-Tab® in the binary mixture. The error bars represents confidence
interval (95%) for three replicates.
The results presented in Figure 35 also suggested lactam formation to be inversely proportional
to the particle size of A-Tab®. It was observed that physical mixtures of gabapentin with a
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smaller particle size fraction (75-125 µm) of A-Tab® showed a greater concentration of lactam
(1.63% mole at 696 h) relative to the lactam content (1.31% mole and 1.10% mole respectively
at 696 h) in physical mixtures with larger size fractions (125-250 µm and 250-500 µm) of ATab® . This observation indicated a key role of the surface molecules of excipient in accelerating
lactam formation. However, a major difference in the specific surface areas of the different size
fractions of A-Tab® was not observed (Figure 35 inset). This observation indicated that a large
fraction of A-Tab’s molecules were contained in the pores on the particle surface. The molecules
within the pores are less likely to be in direct contact with the gabapentin particles. This
observation highlighted the importance of external surface area in driving the degradation
kinetics, relative to the overall specific surface area of the material.

2
A-Tab 75-125 um
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A-Tab 250-500 um
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Figure 35: Effect of excipient particle size on the degradation of gabapentin. (◊) A-Tab
®
®
75-125 µm, (□) A-Tab 125-250 µm, (Δ) A-Tab 250-500 µm. The above data suggests the
role of the external surface area of excipient on the degradation of gabapentin.
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4.3.1. Modification of the Kinetic Model for Degradation of Gabapentin to Incorporate
the Excipient Effect
The existing kinetic model for the degradation of gabapentin does not account for the catalytic
effect of the excipient on gabapentin’s degradation. To incorporate the excipient effect, the
model was modified by the addition of a new, catalyzed pathway between reactive gabapentin
and gabapentin lactam. The rate constant describing the kinetics of the pathway was denoted as
k4 (Figure 36). The expansion of the kinetic model resulted in modification of the differential
equations (Equations 34-38) associated with the model.

Figure 36: Expanded kinetic model for the solid-state degradation of gabapentin in the presence
of excipients. Rate constant k4 was added to the model to represent the rate constant catalyzed by
the excipient molecules (E).
𝐝[𝐠𝐚𝐛𝐚]
𝐝𝐭

= −𝒌𝟏 [𝒈𝒂𝒃𝒂][𝒈𝒂𝒃𝒂∗ + 𝑳] + 𝒌𝟑 [𝒈𝒂𝒃𝒂][𝒈𝒂𝒃𝒂∗ ]

𝐝[[𝐠𝐚𝐛𝐚∗ ]
𝐝𝐭

= 𝒌𝟏 [𝒈𝒂𝒃𝒂][𝒈𝒂𝒃𝒂∗ + 𝑳] − 𝒌𝟑 [𝒈𝒂𝒃𝒂][𝒈𝒂𝒃𝒂∗ ] − 𝒌𝟐 [𝒈𝒂𝒃𝒂∗ ] −

Equation 34
Equation 35

𝒌𝟒 [𝒈𝒂𝒃𝒂∗ ][𝐄]
𝐝[𝐋]
𝐝𝐭
𝐝[𝐋]
𝐝𝐭

= 𝒌𝟐 [𝒈𝒂𝒃𝒂∗ ] + 𝒌𝟒 [𝒈𝒂𝒃𝒂∗ ][𝐄]

Equation 36

= 𝐠𝐚𝐛𝐚∗ (𝐤 𝟐 + 𝐤 𝟒 𝐄)

Equation 37

(𝐤 𝟐 + 𝐤 𝟒 𝐄) = 𝒌∗𝟐

Equation 38
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𝒌∗𝟐 is the newly derived apparent rate constant for the conversion of reactive gabapentin to
lactam. This rate constant is the sum of both the excipient catalyzed and the uncatalyzed rate
constants. 𝐸 represents the concentration (% mole) of surface molecules on the excipient
particle. The concentration of surface molecules on the excipient particle is further described by
combination of physical properties of the excipients as seen in Equation 39.
̅̅̅
𝑺
𝑬
𝑨𝒙 × 𝑵𝑨
𝑬= [ 𝒎
𝒎𝑮 × 𝟏𝟎𝟎] 𝒎𝑬
𝑬
+
𝑴𝒘𝑬 𝑴𝒘𝑮

Equation 39

As seen in Equation 39, ̅̅̅
𝑆𝐸 (m2/g) is the specific surface area of the excipient, 𝐴𝑥 (m2/ molecule)
is the molecular cross-sectional area of the excipients, 𝑁𝐴 (molecules/mole) is Avogadro’s
number, 𝑚𝐸 (g) is the mass of the excipient, 𝑚𝐺 (g) is the mass of gabapentin in the physical
mixture, and 𝑀𝑤 (g/mol.) is the molecular weight of the excipient (𝑀𝑤𝐸 ) or gabapentin (𝑀𝑤𝐺 ).

The representation of 𝐸 using the physical properties of the excipients facilitated the
development of a relationship that accounted for the effect of major physical properties of the
excipients on the apparent rate constant for lactam formation, as seen in Equation 40.
̅̅̅
𝑺
𝑬
𝑨𝒙 × 𝑵𝑨
∗
𝒌𝟐 = 𝒌𝟐 + 𝒌𝟒 × [ 𝒎
𝒎𝑮 × 𝟏𝟎𝟎] 𝒎𝑬
𝑬
+
𝑴𝒘𝑬 𝑴𝒘𝑮

Equation 40

Where 𝑘2 (h-1) is the rate constant for lactam formation in the absence of excipient molecules,
𝑘4 (h-1 mol-1) is the excipient catalyzed rate constant for the conversion of gaba* to lactam in the
presence of excipients.
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The developed relationship had multiple limitations. First, it assumed the total surface molecules
of the excipient to be catalyzing the reaction. This assumption is unlikely especially when
considering simple physical mixtures. Second, the relationship failed to take into account
important physical properties such as the particle size and shape of both the excipient and the
gabapentin particle. Third, the above relationship could lead to overestimation of the
concentration of excipient molecules for catalysis, in the case of porous excipient materials like
A-Tab®, where greater concentration of the molecules would be contained in the pores.

To overcome the above limitations, a factor that could assist in estimating the actual surface area
of the excipient in contact with gabapentin based on the particle size, shape and density of both
gabapentin and excipient particles was included in the model.
The relationship was modified to include a factor (𝑓), as seen in Equation 41.
̅̅̅
𝑺
𝑬
𝑨𝒙 × 𝑵𝑨
∗
𝒌𝟐 = 𝒌𝟐 + 𝒌𝟒 × 𝒇 × [ 𝒎
𝒎𝑮 × 𝟏𝟎𝟎] 𝒎𝑬
𝑬
+
𝑴𝒘𝑬 𝑴𝒘𝑮

Equation 41

Factor (𝑓) represents the fraction surface area of the excipients in contact with gabapentin. This
theoretical estimation was based on the principles of the Komatsu model to determine the contact
area between components in a binary mixture.89

Cumulative lists of all the measured physical properties of the excipients are summarized in
Table 18. The moisture content of the excipients was recorded to be less than 1% w/w for most
excipients, except starch (2.69 ±0.28% w/w) and HPC (1.97±0.38% w/w) due to their ability to
absorb greater amounts of moisture. However, the minimal effect of excipient moisture on the
degradation kinetics of gabapentin in the unprocessed state was observed in chapter 3. The
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excipients under study showed wide variations in their surface properties. As seen in Table 18,
the highest specific surface areas, 54.00 m2/g and 22.40 m2/g, were recorded for the porous
excipients Tri-Tab® and A-Tab®. Lower porosity materials, such as Mono-Tab and starch,
demonstrated lower specific surface area values of 0.70 m2/g and 0.22 m2/g, respectively. The
molecular cross-sectional area varied between 2.30x10-19 m2 and 8.60x10-19 m2 between
excipients. The highest molecular cross-sectional area was recorded for HPC, while, the lowest
molecular cross-sectional area was recorded for A-Tab® (Appendix 2).
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Table 18: Cumulative List for the Various Physical Properties of Excipients

Excipient

𝑀𝑤𝐸
(g/mole)

Tri-Tab®

502.3

3.11
(±
0.004)

54.54

7.2x10-19

0.95
(± 0.12)

0.0122#

Morphol
ogy
&
Circular
ity (C)
C = 0.77

A-Tab®

136.0

2.92
(±
0.009)

22.41

2.3x10-19

0.25
(± 0.03)

0.0118#

C = 0.68

talc

379.3

2.55
(±
0.003)

9.03

5.8x10-19

0.04
(± 0.00)

0.000325#

C =0.63

Emcompr 172.1
ess®

2.61
(±
0.002)

4.53

2.8x10-19

0.22
(± 0.01)

0.0153#

C = 0.63

HPMC

279.0

1.25
(±
0.005)

0.97

6.1x10-19

0.44
(± 0.08)

(0.013
,0.0011,
0.0011)*

C = 0.06

MonoTab

234.0

2.60
(±
0.004)

0.70

4.2x10-19

0.01
(± 0.00)

(0.016,
0.0035,
0035)*

C = 0.07

HPC

321.0

1.23
(±
0.009)

0.93

8.6x10-19

1.97
(± 0.38)

(0.0125,
0.0039,
0.0039)*

C = 0.04

starch

164.0

1.44
(±
0.003)

0.22

6.7x10-19

2.69
(± 0.28)

0.0125#

C= 0.82

#

True
Density
(g/cm3)

̅̅̅
𝑆𝐸
(m2/g)

𝐴𝑥
(m2/molecule)

Moisture
Content
(% w/w)

Particle
Dimension
(cm)

= Mean Feret Diameter for spherical or nearly spherical particle

* = measured length, breadth of a rectangular prismatic excipient particle. Thickness was
assumed to be equal to the breadth.
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The excipients were either spherical (or nearly spherical) or possessed a rectangular prismatic
geometry. Particles with circularity values above 0.6 were considered to be nearly spherical
while those below 0.6 were classified as rectangular prismatic. Amongst the spherical excipients,
the mean Feret diameter recorded was highest in the case of Emcompress® (0.0153 cm) and
lowest in the case of talc (0.000325 cm). On the other hand in the case of excipients with
rectangular prismatic geometry two orientations of the molecule contacting gabapentin could be
imagined. Amongst the excipients, Mono-Tab demonstrated greater particle dimensions
(l = 0.016 cm and b = 0.0035 cm) relative to the particle dimensions for HPMC (l = 0.0130 cm
and b = 0.0011 cm) and HPC (l = 0.0125 cm and b = 0.0039 cm).

The total molecular concentration on the surface of the excipient particle, capable of accelerating
gabapentin’s degradation was calculated and is reported in Table 18. As expected, the specific
surface area of the excipient particle played a critical role where excipients with greater specific
surface area values, such as Tri-Tab® and A-Tab® had greater concentrations of total surface
moles available for interaction. Similarly, excipients with lower specific surface area values,
such as starch and Mono-Tab displayed a lower concentration of molecules at the surface.
Amongst the excipients, HPC despite of relatively higher surface area value than Mono-Tab,
showed a similar concentration of molecules at the surface; this was due to the higher molecular
cross-sectional area of HPC relative to that of Mono-Tab. It was observed that the molecular
cross-sectional area and specific surface area of the excipients together played an important role
in estimating the total surface molar concentration. After addition of the factor (𝑓) to estimate
the fraction surface area of the excipient particle in contact with gabapentin, a more accurate
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representation of the concentration of excipient molecules expected to be in contact with
gabapentin was reported as seen in Table 19.

Table 19: Estimation of surface molar concentration on the excipient particle available for
catalyzing lactam formation

Excipients

𝑁𝐸

Total % Mole
on Surface of
Excipient
Particle

Tri-Tab®
A-Tab®
Emcompress®
talc
starch
HPC
HPMC
Mono-Tab

0.05
0.06
0.03
859.64
0.10
0.59
4.90
0.30

1.339
0.453
0.091
0.155
0.002
0.012
0.019
0.013

𝑓

0.00007
0.00026
0.00117
0.00736
0.05377
0.02188
0.33649
0.15980

Estimated
Actual % Mole
on Excipient
Particle in
Contact with
Gabapentin
0.00010
0.00012
0.00010
0.00114
0.00015
0.00081
0.00241
0.00084

The value for (𝑓) (0.02-0.33) was estimated to be higher in the case of particles with a
rectangular shape relative to the estimated value of (𝑓) (0.00007-0.053) in the case of spherical
particles. This was due to the greater PCA between two rectangular particles relative to a sphere
and a rectangular-shaped particle. However, in the case of starch and gabapentin physical
mixture, the value of (𝑓) (0.053) was higher relative to other spherical excipients due to the
greater contact surface area (CSA) between gabapentin and starch particles relative to most other
spherical excipients. Hence the total estimated surface area of starch in contact with gabapentin
was higher relative to the total available surface area of starch in the mixture.

Talc, despite its spherical shape, had a greater magnitude for (𝑓) relative to other spherical
particles of excipients due to the smaller particle size of talc relative to other excipients, which
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resulted in a higher estimated number of talc particles in contact with gabapentin. In the case of
HPMC, greater numbers of HPMC particles (4.9 particles) were estimated to be covering a
surface of gabapentin relative to other excipients in the study, which was a result of its higher
estimated (𝑓) value. The actual surface molecules of the excipients in contact with gabapentin
were calculated to be greater in the case of talc and HPMC due to the higher estimated value of
(𝑓) relative to other excipients in the study.

In summary, the theoretically estimated fraction of surface moles in contact with gabapentin was
found to be dependent mainly on the shape, size, density and molecular weight of the excipient.
This estimation facilitated calculation of the rate constant k4 using Equation 41 for lactam
formation in the presence of excipients (Figure 37).
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Figure 37: Estimated catalytic rate constant k4 (h-1mol-1) for lactam formation in the
presence of excipients. The plot is in logarithmic scale for the y-axis to show the magnitude
of difference in the effect of excipient type on gabapentin’s degradation. Maximal effect is
shown by inorganic basic excipients relative to inorganic acidic excipients and polymers.
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The estimation of rate constant k4 helps in determining a role of the excipient’s chemical
properties in catalyzing lactam formation. However, the present data was unable to pinpoint a
direct connection between the rate constant k4 and a chemical property of the excipient.
However, the results indicated a greater impact of inorganic salts of basic nature (Tri-Tab® (pKa
12.12), A-Tab® (pKa 7.4), talc (pKa 9.19), and Emcompress® (pKa 7.4)) relative to inorganic
excipients of acidic nature (Mono-Tab (pKa 2.12)). Polymers (HPMC, HPC, and starch) had a
lower impact on the degradation of gabapentin relative to the inorganic excipients. A possibility
of a general base catalysis similar to that observed in the solution state degradation kinetics of
gabapentin cannot be ignored. In the case of polymers and organic excipients, it could be
hypothesized that the presence of impurities of a basic nature could be driving the catalysis of the
reaction. However, further investigation will have to be planned in order to test this hypothesis.
Nevertheless, to make a strong conclusion, and relate a particular chemical property of the
excipients to affect lactam formation, the existing library of excipients will have to be expanded.

Currently, the ability to estimate k4 from the developed relationship helps to facilitate excipient
selection and the separation of a certain chemical class of excipients capable of catalyzing
gabapentin’s degradation.

On further validation, the model has the potential to be used as a tool in screening excipients and
facilitating their selection for solid formulations of gabapentin. The model will enable risk
assessment and identify formulations exceeding the regulated lactam content upon alterations in
the physical properties of excipients due to batch-to-batch variation or change in the source for
excipient procurement.
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4.4. Conclusion
The results confirmed a catalytic effect of the excipient concentration on gabapentin’s
degradation profile. To account for the effect of excipient properties, the existing kinetic model
for gabapentin’s degradation was modified, and rate constant k4 for lactam formation in the
presence of excipients was incorporated. On modification of the kinetic model, the rate constant
k2* (combination of rate constants k2 and k4) was defined as the “apparent rate constant” that
accounted for lactam formation in the presence and absence of excipients.

Referring back to the research hypothesis, which stated that physicochemical properties (such
as specific surface area, molecular weight, particle size, particle shape and, acidic or basic
strength) of the excipients will accelerate the solid-state degradation of gabapentin,
increasing the rate constant (k2) for lactam formation. The results from this chapter proved
the hypothesis and concluded major physical properties of the excipient such as their particle
size, morphology, specific surface area, molar weight, and molecular cross-sectional area to be
impacting the rate constant (k2) for lactam formation. However no specific chemical properties
of the excipients were found to be impacting the lactamization kinetics.

An inverse relationship between the particle size of the excipient and the rate of lactam
formation was concluded. This finding prompted a strong need to theoretically estimate the
actual surface moles of the excipient in contact with gabapentin after considering for the effect of
particle size, shape, and density. Model expansion resulted in the development of a relationship
between the apparent rate constant (k2*) and surface molar concentration of the excipient in
contact with gabapentin based on the physical properties of the excipients. The proposed
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relationship has the potential to be used as a tool to assess the effect of different physical and
chemical properties of the excipient on the solid-state degradation of gabapentin.
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Chapter 5

Effect of Compaction and Powder Properties of Excipients on the Solid-State
Degradation of Gabapentin
5.1. Introduction
In chapter 4 we studied the effects of the physical properties of excipients on gabapentin’s
degradation. We also developed a theoretical model to predict how lactam content changes over
time as excipient properties change. The results in chapter 4 are based on the physical mixing of
gabapentin and excipients. Commercially, gabapentin is mainly available as tablets. Hence, it is
also important to study the effects of compaction.

We hypothesized that in addition to the catalytic effect of excipients, compaction stress will
accelerate lactam formation. It was expected that in the case of a highly crystalline drug like
gabapentin, compaction stress would cause crystal damage and increase the concentration of
reactive gabapentin molecules available for lactam formation. It was also expected that
compaction in the presence of excipients would accelerate lactam formation by increasing the
area of contact or the number of points of contact between gabapentin and the excipient
molecules.

In this chapter we will study the effect of compaction stress, compact porosity, compaction
energy, yield pressure and moisture content of the excipient as potential factors affecting the
solid-state degradation of gabapentin.
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5.2. Materials and Methods
5.2.1. Materials
Compacts for the study were prepared using physical mixtures of gabapentin and excipients in a
1:1 proportion. The excipients used for the study were dibasic calcium phosphate dihydrate
(Emcompress®, E. Mendell. Co. Inc, New York), modified corn starch (Uni-pureTM DW,
National Starch LLC, New Jersey), hydroxypropyl cellulose (HPC, Klucel EF®, Ashland
Aqualon Functional Ingredients, Delaware), hydroxypropyl methyl cellulose (HPMC,
MethocelTM E50 Prem LV, The Dow Chemical Co., Michigan) and talcum (Talc, Fisher
Scientific, Massachusetts). All other reagents and solvents used for the analytical quantitation
were HPLC grade.

5.2.2. Material Pretreatment
All solid materials including gabapentin and the excipients were stored under controlled
conditions of temperature and humidity (21°C and 33% RH) for 1 week prior to compaction. The
materials were not controlled for their particle size and were used as received from the supplier.

5.2.3. Determination of Moisture Content
The moisture content (% w/w) of the excipients was determined using thermogravimetric
analysis (TGA Q-500, TA Instruments, Delaware). The average and standard deviation of two
replicate measurements has been reported.
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5.2.4. True Density Determination
The true density was determined using helium pycnometry (Model: SPY-6DC, Quantachrome
Instruments, Boynton Beach, Florida) as described in chapter 4 and was performed in triplicates
for each excipient.

5.2.5. Study Protocol
Gabapentin and excipients were mixed individually for every compact, in a 1:1 weight ratio
(200 mg each) in a geometric proportion. Batch mixing of gabapentin with the excipients was
avoided to eliminate sampling related inhomogeneity issues. In the case of gabapentin without
excipients, 400 mg of gabapentin was weighed for compaction. Compacts of the physical
mixtures (n = 3/time-point) were prepared using Instron Universal Testing System (Model 5869,
Instron Corporation, Norwood, Massachusetts) at a compaction speed of 240 mm/min to a
maximum pressure of 36.6 kN, measured using a 50 kN load cell in a 13 mm steel cylindrical
die. Decompression using the same crosshead speed began immediately after the maximum load
was reached. Punch separation distance was corrected for deformation of the tooling. This was
done by adding the displacement measured during compression of the punches in an empty die to
the punch separation distance measured during formation of each compact. The compact
thickness and the diameter were measured immediately after ejection from the die using a set of
digital calipers. Extra compacts for every set of gabapentin-excipient mixtures were prepared in
triplicate and stored for 4-5 consecutive days under ambient temperature (21°C) and humidity
conditions (31-33% RH) to allow for viscoelastic relaxation. This step was important to measure
the “out of die” thickness of the tablets after the relaxation process in order to calculate the
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compact porosity. This measurement of the “out of die” thickness was especially critical in the
case of gabapentin compacts with viscoelastic materials like starch.

Compact porosity was calculated using the mass of the compact and the true density of
individual components using Equation 42. In the case of physical mixtures, the true density of
the mixture was calculated as the weighted sum of the true densities of the individual
components based on their mass ratio.
𝜺=𝟏−

𝟒𝒎
𝝅 (𝑫)𝟐 𝒕𝝆

Equation 42

In the above equation, 𝜀 denotes porosity, 𝑚 is mass of the compact, 𝐷 is the diameter of the
compact, t is the compact thickness after viscoelastic relaxation, and 𝜌 is the true density of the
physical mixture.

As discussed in chapter 1, the Heckel model for consolidation was used to calculate the yield
pressure (𝑃𝑦 ) of different physical mixtures, as per Equation 21.

The mechanical energy values were determined using the Blue Hill Software Package (Instron,
Norwood, Massachusetts). The work of compression (Wc) and work of decompression (Wd)
were determined by integration of the force vs. displacement plots. Work of compression values
represent the amount of work absorbed by the sample during compression that is not released
during decompression.
𝑾𝒄/𝒅 = 𝑾𝒄 + 𝑾𝒅

Equation 43

In equation 43, 𝑊𝑐/𝑑 represents the irreversible work (J/g) utilized in making the compact.
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The compacts (n = 3) for the gabapentin-excipient physical mixtures for every time point were
stored under accelerated conditions of temperature and humidity (50°C and 5% RH) and
analyzed for the concentrations of gabapentin and lactam using a validated HPLC analytical
method across 624 h.

The expanded kinetic model for the solid-state degradation of gabapentin as derived in chapter 4
was applied to the generated data.1 The Runge-Kutta 4th order numerical approximation method
was used to solve the series of differential equations defining the kinetic model.1The data
collected was parameterized by non-linear regression using the Solver function (Excel® 2010).
The initial values for the parameters were the optimized parameter estimates obtained after
parameterizing the stability data in chapter 3.

The parameters expected to change on compaction and with the presence of excipients included,
gaba0*, due to increased concentration of the reactive gabapentin molecules on exposure to
mechanical stress, and the rate constant k4 (part of k2*), due to the greater contact area between
gabapentin and excipients. The possible effect of excipient moisture in stabilizing the
degradation of gabapentin could result in alteration in the value of k3. Hence, gaba0*, k2*, and k3
were optimized, followed by the optimization of k1. The values for k3 and k1 were constrained to
be greater than 10-8 to obtain non-zero estimates for the parameters.

The nature of the differential equation for lactam formation, as shown in Equation 36,
demonstrates mathematical links between k2* and gaba0*. We have not attempted to separate their
effects in compacted samples. We have therefore compared the initial rate for lactam formation
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represented by k2*gaba0* to determine the effect of compaction and the presence of excipients on
the degradation of gabapentin.

5.3. Results and Discussion
Lactam formation results for compacted mixtures can be seen in Figure 38. The results
demonstrate accelerated lactam formation in compacted physical mixtures of gabapentin with
excipients relative to gabapentin compacted by itself. Application of the expanded kinetic model
to the data resulted in good fit (indicated by dashed line in Figure 38) between the modelpredicted data and the observed data points with low sum of square error (SSE <0.005) values
across the different gabapentin-excipient mixtures.
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Figure 38: Effect of compaction and the presence of excipients on the solid-state
degradation of gabapentin. Dashed lines indicate model-predicted data. The measured
lactam concentration is an average of three replicates in gabapentin compacts and
gabapentin-excipient compacts, and the error bars represent a 95% confidence interval.
The effect of compaction was especially prominant when comparing the slope of the initial
lactam formation for compacted gabapentin with uncompacted gabapentin in Figure 39.
The value of k2*gaba0*, which represents the initial rate of lactam formation, was found to be
approximately 90% higher in the case of compacted gabapentin in the absence of any excipients
relative to uncompacted gabapentin.
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Figure 39: Effect of compaction on gabapentin’s degradation. The data points represent
the concentration of lactam % mole over time (h) in gabapentin compacts (n = 3) and
gabapentin uncompacted (n = 3). The error bars represent a 95% confidence interval.
In the case of compacts of physical mixtures of gabapentin and excipients, the accelerated effect
of lactam formation is a combined effect of compaction conditions and the catalytic effect of
excipients. Hence, to understand the effect of compaction, the percent increase in the initial rate
of lactam formation between the gabapentin physical mixtures and their compacts was compared
as seen in Figure 40.
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Figure 40: Comparison of the initial lactamization rate (k2*gaba0*) between the gabapentinexcipient physical mixtures and compacts. The arrows indicate the percent increase in the
values of the initial lactamization rate in the case of the compacts of the physical mixtures
relative to the value of the initial lactamization rate for physical mixtures.
The initial rate of lactam formation (k2*gaba0*) increased substantially (68%) in the case of
compacts of gabapentin with Emcompress® and HPMC relative to the value of k2*gaba0* in their
physical mixtures. This effect can also be observed as an increase in the initial slope in the
lactam formation profiles for mixtures and compacts of gabapentin with excipients in Figure 41
and Figure 42. Compaction is likely to increase the contact area between gabapentin and the
excipient particle, accelerating lactam formation by affecting the value of k2*. It is important to
remember that the rate constant k2* incorporates rate constant k4, which is catalyzed by the
concentration of molecules on the surface of the excipient particle in contact with gabapentin. On
the other hand, compaction pressure is also likely to increase the concentration of reactive
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disordered molecules (gaba0*) of gabapentin, thus accelerating the initial rate of lactam
formation.
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Figure 41: Effect of compaction on gabapentin’s degradation in the presence of
Emcompress®. The legends represent lactam concentration (%mole) over time in the case
of physical mixtures and compacts of gabapentin and Emcompress ®. The error bars
represent a 95% confidence interval (n = 3).
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Figure 42: Effect of compaction on gabapentin’s degradation in the presence of HPMC.
The legends represent lactam concentration (%mole) over time in the case of the physical
mixtures and compacts of gabapentin and HPMC. The error bars represent a 95%
confidence interval (n = 3).
It was hypothesized that yield pressure would influence the degradation kinetics of gabapentin.
This was expected, due to the possible impact of this material property on the extent of
gabapentin’s fragmentation, increasing the area of contact between gabapentin and excipient
particles. To understand the effect of yield pressure, a plot of yield pressure for the physical
mixtures and initial rate of lactam formation is shown in Figure 43.

It was observed that gabapentin-excipient physical mixtures with higher yield pressure
(>200 MPa), which deform predominantly via brittle fracture, were responsible for a greater
increase in the rate of initial lactam formation relative to other excipients in the study. Along
with the materials deforming by brittle fragmentation, the physical mixture of gabapentin and
HPMC undergoing plastic deformation and with a low yield pressure value (<75 MPa) was also
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seen to be impacting the initial rate of lactam formation. Hence, the yield pressure of the
excipients can be considered one of the critical factors that need to be further explored.
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Figure 43: A plot suggesting the relationship between the initial lactam formation rate and
the yield pressure of gabapentin-excipient physical mixtures.
Compaction of gabapentin with talc demonstrated no substantial increase in the initial rate of
lactam formation relative to their physical mixtures as seen in Figure 44. When comparing the
value of k2*gaba0* for the compacts and the physical mixture of gabapentin with talc, a 28%
increase was observed. The increase in the value of k2*gaba0* was relatively lower than that
observed in the case of the gabapentin-Emcompress® mixture and compacts with a similar
deformation mechanism. This observation was thought to be due to the finer size (~3 um) of talc
particles and their tendency to coat the surface of gabapentin in the physical mixture (Figure 44
(inset)). The coating of talc on the surface of gabapentin is thought to result in a greater level of
initial contact between the two materials. The contact area between gabapentin and talc was
122

thought to not increase substantially on compaction. However, it is important to point out that the
initial data points in the degradation profiles for the gabapentin and talc mixtures and the
compacts have less number of data points to make a conclusive statement. Collecting more data
points across the initial degradation profile will be important to better support our conclusion.
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Figure 44: Effect of compaction on gabapentin’s degradation in the presence of talc. The
legends represent lactam concentration (% mole) over time in physical mixtures and
compacts of gabapentin and talc. The trend lines across the data points rationalize the
slight increase in the initial slope for lactam formation. The error bars represent a 95%
confidence interval (n = 3). The inset picture shows a morphological representation of
gabapentin particles coated by talc particles in their physical mixture.
The excipient that did not show a substantial increase in lactam formation upon compaction with
gabapentin was starch as seen in Figure 45. It is important to highlight that amongst the
excipients in the study, starch had the highest moisture content of 9.09% w/w. The literature
123

findings strongly suggest that moisture stabilizes processed gabapentin by healing the disordered
molecules. Hence, we cannot rule out the effect of the moisture contained in starch to be
stabilizing the degradation of gabapentin on compaction.
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Figure 45: Effect of compaction on gabapentin’s degradation in the presence of starch. The
legends represent lactam concentration (% mole) over time in the case of physical mixtures
and compacts of gabapentin and starch. The error bars represent a 95% confidence
interval (n = 3).
To understand if the moisture contained within the excipients could be one of the factors
affecting gabapentin’s degradation, k2*gaba0* and the moisture content (% w/w) of the excipients
were plotted as in Figure 46. The results showed a potential connection between the rate of initial
lactam formation and the moisture content of the excipients.
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Figure 46: A relationship plot of the initial rate for lactam formation and moisture content
of the excipients. A possible stabilization effect of excipient moisture on lactam formation is
suggested.

Another excipient that did not show a significant increase in lactam formation on compacting
with gabapentin was HPC, as seen in Figure 47. The increase in the rate of initial lactam
formation of the gabapentin-HPC compact was lower relative to the increase in the rate of initial
lactam formation for the gabapentin-HPMC compact. This was in spite of the moisture content
and deformation properties of HPC and HPMC being similar. Interestingly, as seen in Figure 48,
the gabapentin compact with HPC demonstrated the lowest porosity value (0.06) of all
gabapentin-excipient compacts. HPC was also one of the excipients with higher moisture
content. Lower porosity of the compact could suggest greater contact area between gabapentin
and HPC. On the other hand, the higher moisture content of HPC in the compact with high solid
fraction could potentially stabilize gabapentin by creating a microenvironment with high relative
humidity within the compact. Hence, understanding the effect of HPC on gabapentin’s
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degradation on compaction will require further studies that isolate the effects of compact
porosity, excipient moisture, and excipient yield pressure.
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Figure 47: Effect of compaction on gabapentin’s degradation in the presence of HPC. The
legends represent lactam concentration (% mole) over time in the case of physical mixtures
and compacts of gabapentin and HPC. The error bars represent a 95% confidence interval
(n = 3).
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Figure 48: Comparative plot for porosity of the compacts of gabapentin with excipients.
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The energy utilized in compact preparation was hypothesized to affect the rate of initial lactam
formation. Results indicated no substantial effect from this factor, as observed in Figure 49.
However, it is difficult to make any conclusive statement since a number of other confounding
factors could be responsible for the observed results.

It is important to note that the data collected from this study is preliminary and only identifies
potential factors that could be playing a role in gabapentin’s degradation on compaction. Future
studies can be designed to better quantify the relationship between lactam formation rate and
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Figure 49: A relationship plot for the initial rate of lactam formation and the work of
compression for compacts of gabapentin with excipients. Data indicates poor correlation
between the two factors.
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The results did not show any substantial effect from the processing conditions and the presence
of excipients on the rate constants k1 and k3. No substantial difference in the magnitude of k3 was
observed between the physical mixtures and the compacts of gabapentin with excipients, as seen
in Figure 50.
0.00016
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0.00014

compact

k3 (mol-1h-1)

0.00012
0.0001
0.00008
0.00006
0.00004
0.00002
0
Talc

Ditab
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Figure 50: Effect of excipients on the rate constant k3 in gabapentin’s degradation kinetics

5.4. Conclusion
Compaction pressure accelerated the initial rate of lactam formation in pure gabapentin compacts
relative to unprocessed gabapentin. This effect was potentially due to an increase in the
concentration of reactive molecules available for lactamization. Accelerated lactam formation in
compacts of gabapentin with excipients was expected to be a result of the increased
concentration of reactive gabapentin (gaba0*) and the increased catalytic effect of excipients due
to more intimate contact between gabapentin and the excipients. Rate constants k1 and k3 were
not impacted substantially by the application of compaction pressure or by the powder properties
of excipients.
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The above preliminary study suggested a possible effect of yield pressure, moisture content, and
particle size of the excipient, and compact porosity on the initial rate for lactam formation in
gabapentin-excipient compacts. Further studies are needed to understand the impact of the
identified factors on gabapentin’s degradation and to quantify the relationship between the
factors and the initial rate of lactam formation.
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Chapter 6
Conclusion
The objective of the presented research was to understand the role of excipients and compaction
conditions on the solid-state degradation of gabapentin. It was hypothesized, that
physicochemical properties (such as specific surface area, molecular weight, particle size,
particle shape and, acidic or basic strength) of the excipients will accelerate the solid-state
degradation of gabapentin, increasing the rate constant (k2) for lactam formation. The
degradation kinetics, predominantly the initial rate for lactam formation will be further
accelerated by compaction of the gabapentin-excipient physical mixtures.

To test this hypothesis, five specific aims were designed. The first specific aim was to develop
and validate (ICH Q2A guidelines) a robust analytical method for accurate quantitation of
gabapentin and lactam. The results for studies associated with this aim are discussed in chapter 2.
The second specific aim of the project as discussed in chapter 3 was to provide evidence for the
effect of excipients on the solid-state degradation of gabapentin in the absence of any processing
conditions. The third specific aim of the project as discussed in chapter 4, was to understand the
effect of excipient concentration and its particle size on the degradation of gabapentin in solidstate. This aim also included expansion of the existing kinetic model to account for the effect of
excipient properties. The fourth specific aim, also discussed in chapter 4, was to develop a
mechanistic relationship between the physical properties of the excipient (such as shape, size,
density, molecular cross sectional area, molecular weight, and surface area) with the rate
constant for lactam formation. The relationship has the potential to estimate the effect of
excipients based on their physical and chemical properties. The final specific aim of the project
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as discussed in chapter 5 was to understand the role of compaction conditions and powder
properties of excipients on the solid-state degradation of gabapentin.

The results in Chapter 2 highlighted the successful validation of an isocratic HPLC-UV
analytical method, as per the ICH Q2A guidelines. The results confirmed the purity of the
procured gabapentin sample to be comparable to that of the acquired USP reference standard.
Inter-day and intra-day measurements, demonstrated the analytical method to be accurate,
precise and robust. The method demonstrated specificity with respect to the elution of gabapentin
and lactam in the presence of excipients. The results, confirmed absence of interference either
from the filter membrane or from the excipients for extraction of lactam and gabapentin in
solution. Lactam was found to be stable both in the mobile phase and in the sample solvent, for
the entire duration of the study. On the other hand, the degradation rate of gabapentin in solution
was observed to be too low to interfere with the results of solid-state degradation studies.

Results from chapter three provided strong evidence that excipients accelerate the degradation of
unprocessed gabapentin to lactam in solid-state. Application of the existing kinetic model
highlighted that the excipients significantly (p>0.05) affect the initial rate of lactam formation.
This initial rate is described by rate constants k2 and the concentration of reactive gabapentin
molecules (gaba0*). The results partly proved the hypothesis that “properties of the excipients
will accelerate the rate constant (k2) for spontaneous lactam formation”. Fixing a lower value of
gaba0* and a value of k2, as established previously in the literature, successfully predicted the
gabapentin degradation profile with a high R2 value (>0.97). However, the same lower value of
gaba0* was unable to fit the data for the gabapentin-excipient binary mixture, which had the
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highest lactam formation rate. The higher estimated value for gaba0* in most cases of gabapentinexcipient binary mixtures was the result of high lactam formation, measured in the initial time
period of the stability study. As per the model assumption, the initial lactam formation is
predominantly due to the spontaneous conversion of gaba0*. Thus, to observe the high initial
lactam content as seen in the results from chapter 3, a greater concentration of gaba0* will have to
be present as indicated by the model predicted estimate. The lowest value of gaba0* that provided
a good fit (R2<0.99) was 3% mole. Fixing the value of gaba0* lower than 3% mole resulted in a
poor model fit to the data. Interestingly, higher value of gaba0* provided a good fit for the
gabapentin data with an R2 value of (>0.97) and sum of square error value of 0.0005. The fit was
comparable (similar values for R2 and SSE) to that obtained for the gabapentin data with lower
value of gaba0*.

The lower estimated value of gaba0* in previously established studies is entirely based on the
data generated after milling gabapentin in the absence of excipients. Thus, greater initial lactam
formation is attributed to the higher concentration of gaba0* on milling. However, after
accounting for the catalytic effect of the excipients on the rate constant k2, the value of gaba0*
was estimated to be 3% mole for unprocessed gabapentin present in all the binary mixtures. The
concentration of reactive gabapentin molecules was defined as the sum of all surface molecules
and other disordered molecules in the crystal. The concentration of reactive molecules was
unexpectedly higher and hence will require further investigation.

The rate constant k2 showed a significant (p<0.05) increase in the presence of excipients relative
to its value for gabapentin. Amongst the excipients tested, inorganic excipients (Tri-Tab®,
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A-Tab®, Talc and Emcompress®) were seen to impact the degradation kinetics of gabapentin far
more than polymers (HPMC, HPC and starch). Rate constants k1 and k3 were relatively less
affected in the presence of most excipients. However, in physical mixtures of gabapentin with
Tri-Tab® and A-Tab® the value of k1 and k3 was estimated to be significantly lower than that of
gabapentin by itself. This effect is likely due to the higher magnitude (x100) of k2 relative to k1
and k3, resulting in masking the branching and termination phase in the solid-state degradation
profile. The branching phase described by rate constants k1 and k3, is observed clearly in the case
of the degradation profiles for gabapentin, starch and Mono-Tab, which have lower values of k2.

Concentration dependent catalytic effect of the excipients was observed in the results from
chapter 4 where, as the mass of the excipient in the binary mixture with gabapentin increased,
there was an increase in the lactam content. This concentration dependent catalytic effect of the
excipients was incorporated into the existing kinetic scheme. The kinetic model was expanded by
addition of rate constant k4, surface molar concentration of excipients (E) and apparent rate
constant k2*. Apparent rate constant k2*, was the sum of catalytic rate constant k4 and
uncatalyzed rate constant k2.
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The final set of differential equations to predict lactam formation for the degradation of
gabapentin in the presence of excipients would be as follows:
𝐝[𝐠𝐚𝐛𝐚]
𝐝𝐭

= −𝒌𝟏 [𝒈𝒂𝒃𝒂][𝒈𝒂𝒃𝒂∗ + 𝑳] + 𝒌𝟑 [𝒈𝒂𝒃𝒂][𝒈𝒂𝒃𝒂∗ ]

𝐝[[𝐠𝐚𝐛𝐚∗ ]
𝐝𝐭

= 𝒌𝟏 [𝒈𝒂𝒃𝒂][𝒈𝒂𝒃𝒂∗ + 𝑳] − 𝒌𝟑 [𝒈𝒂𝒃𝒂][𝒈𝒂𝒃𝒂∗ ] − 𝒌𝟐 [𝒈𝒂𝒃𝒂∗ ] −

Equation 44
Equation 45

𝒌𝟒 [𝒈𝒂𝒃𝒂∗ ][𝐄]
𝐝[𝐋]
𝐝𝐭

Equation 46

= 𝐠𝐚𝐛𝐚∗ 𝒌∗𝟐

(𝐤 𝟐 + 𝐤 𝟒 𝐄) = 𝒌∗𝟐

Equation 47

In the above equations:
k1 (mol-1h-1) is the autocatalytic rate constant
k2 (h-1) is the uncatalyzed rate constant for spontaneous lactam formation
k3 (mol-1h-1) is the termination rate constant catalyzed by environmental moisture
k4 (mol-1h-1) is the excipients catalyzed rate constant for spontaneous lactam formation
k2*( h-1) is the apparent rate constant for spontaneous lactam formation, which is the sum of both
the catalyzed and the uncatalyzed rate constant
gaba (% mole) is the concentration of stable gabapentin molecules
gaba* (% mole) is the concentration of reactive gabapentin
L (% mole) is the lactam concentration
t (h) is time.

Total molar concentration (E) on the surface of the excipient particle was represented using the
specific surface area, the molecular cross sectional area and the molecular weight of the
excipient. Results in chapter 4, also demonstrated an effect of excipient particle size on the rate
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of lactam formation. Increasing particle size of the excipient molecules demonstrated decrease in
rate of lactam formation. This finding highlighted the importance of estimating actual surface
contact between gabapentin and the excipient based on their particle morphology and size. The
fraction of molar concentration on the excipient surface which is in contact with gabapentin, was
estimated (based on particle size, true density, the morphology of the excipient and gabapentin),
by using the Komatsu model.89 Results from chapter 4 proved the hypothesis that both the
physical and the chemical properties of the excipients affect the lactamization kinetics.

The major physical properties of the excipients were measured and incorporated into the
developed model which helped estimate the rate constant k4 as it is affected by chemical
properties of the excipients. Estimation of the excipient catalyzed rate constant, indicated greater
impact of inorganic salts of basic nature (Tri-Tab® (pKa 12.12), A-Tab® (pKa 7.4), Talc (pKa
9.19) and Emcompress® (pKa 7.4)) relative to inorganic excipients of acidic nature (Mono-Tab
(pKa 2.12)). Polymers (HPMC, HPC and starch) had a lower impact on the degradation of
gabapentin relative to the inorganic excipients. However, considering the limited number of
excipients used, it was difficult to strongly conclude that any particular chemical property was
impacting degradation kinetics of gabapentin. Further expansion of the excipient library will be
required to establish relationships between chemical properties of the excipients and the rate
constants describing the degradation kinetics.

Comparing the initial rate (k2*gaba0*) of lactam formation between gabapentin-excipient physical
mixtures and their compacts in Chapter 5, showed that compaction pressure and powder
properties affected gabapentin’s degradation. Results from the study proved the hypothesis that
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“The degradation kinetics, predominantly the initial rate of lactam formation will be further
accelerated by compaction of gabapentin-excipient physical mixtures”. Results indicated
accelerated initial rate of lactam formation in case of compacted gabapentin. This is
hypothesized to be due to damage caused to its crystals, which would lead to increased
concentration of reactive molecules. Results also indicated the potential role of compact porosity,
yield pressure of physical mixtures, and moisture content of excipient and excipient particle size
in accelerating lactam formation.

In summary, excipients impacted solid-state degradation of gabapentin. This impact was
incorporated into the previously established kinetic model. The developed relationship between
the apparent rate constant for lactam formation and the physical properties of excipients can be
further explored, as a risk assessment tool. This tool would help predict lactam formation in
gabapentin formulations over time, with variations in the physical properties of excipients and
compaction conditions.
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Appendix 1
Supporting data Chapter 1
1. Analytical method validation: Specificity (matrix effect)


The results confirmed the absence of excipient interaction in the elution of
gabapentin and lactam.



Excipient solutions were analyzed using the HPLC technique, to identify for any
peaks specific to the excipients, interfering with the elution of either gabapentin
and/or lactam



The concentration of the excipient solution (4mg/ml) was selected based on the
expected concentration in the solutions of their physical mixtures and compacts
with gabapentin.
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Figure 51: The chromatogram for HPC at a concentration of 4 mg/ml
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Figure 52: The chromatogram for HPMC at a concentration of 4 mg/ml
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Figure 53: The chromatogram for starch at a concentration of 4 mg/ml
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Figure 54: The chromatogram for talc at a concentration of 4 mg/ml
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Figure 55: The chromatogram for Emcompress® at a concentration of 4 mg/ml
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Figure 56: The chromatogram for Tri-Tab® at a concentration of 4 mg/ml
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Figure 57: The chromatogram for A-Tab® at a concentration of 4 mg/ml
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Figure 58: The chromatogram for Mono-Tab at a concentration of 4 mg/ml
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Appendix 2
Supporting documentation for chapter 4
Specific surface area measurements


Multipoint measurements were performed using nitrogen vapor adsorption data with
subsequent application of the BET model



Material weight: 1.00-1.5 g



Samples were outgassed at high temperatures (50-200°C depending on the material) for
more than 24 h.



Single sample of each excipient was analyzed



The moles of nitrogen adsorbed at each partial pressure was analyzed using the BET
equation (Equation 23)



Specific surface area was calculated as the quotient of the samples total surface area and
mass
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Figure 59: A multi-point BET measurement for Kaolinite reference standard.
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Figure 60: A multi-point BET measurement for Alumina reference standard.
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Figure 61: A multi-point BET measurement for Tri-Tab®
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Figure 62: A multi-point BET measurement for A-Tab® 75-125µm
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Figure 63: A multi-point BET measurement for A-Tab® 125-250µm
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Figure 64: A multi-point BET measurement for A-Tab® 250-500 µm
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Figure 65: A multi-point BET measurement for Mono-Tab®

152

0.25

0.30

0.3
y = 0.914x + 0.045
R² = 0.999

P/P0/V[1-(P/P0)]

0.25
0.2
0.15
0.1

SSA: 4.54 m2/g

0.05
0
0.00

0.05

0.10

0.15

0.20

0.25

0.30

P/P0

Figure 66: A multi-point BET measurement for Emcompress®
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Figure 67: A multi-point BET measurement for starch
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Figure 68: A multi-point BET measurement for HPMC
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Figure 69: A multi-point BET measurement for HPC
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Figure 70: A multi -point BET measurement for talc
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Molecular Cross-Sectional area measurements

Computation of molecular cross-sectional area for excipients,
Step 1: Structures of the excipients were constructed using Chem-Draw®
Step 2: Transformation of 2-D structures to 3-D structures was performed on MOE®
Step 3: Energy minimization was performed using MMF94X force field in MOE®
Step 4: Bond distances for different molecular orientations of the excipients were measured. Two
major orientations of the molecules on the surface of the excipient particle were assumed.
Step 5: Surface for the excipient structure in 3-D was generated. The colors on the surface were
indicative of H-bonding sites (Pink), hydrophobic sites (Blue), and mild polar sites (green).
Step 6: The final distances (length and breadth) across the molecular surface for the two
orientations were measured and the van-del-Waals radii for atoms was added to the measured
bond lengths
Step 7: The molecular cross sectional area (𝐴 = 𝜋(length major axis × length minor axis))
was calculated assuming an ellipsoidal geometry at the cross section.
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Figure 71: Computation of molecular cross-sectional area for A-tab®
A. Measured dimensions (bond length measuring length and breadth) for Orientation 1 of the
molecule. B. Measured dimensions for orientation 2 of the molecule. C. Surface constructed for
the molecule in orientation 1. D. Surface constructed for the molecule in orientation 2. The
surface accounts for the van-der Waals radii of atoms.
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Figure 72: Computation of molecular cross-sectional area for Emcompress®
A. Measured dimensions (bond length measuring length and breadth) for Orientation 1 of the
molecule. B. Measured dimensions for orientation 2 of the molecule. C. Surface constructed for
the molecule in orientation 1. D. Surface constructed for the molecule in orientation 2. The
surface accounts for the van-der Waals radii of atoms.
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Figure 73: Computation of molecular cross-sectional area for HPC
A. Measured dimensions (bond length measuring length and breadth) for Orientation 1 of the
molecule. B. Measured dimensions for orientation 2 of the molecule. C. Surface constructed for
the molecule in orientation 1. D. Surface constructed for the molecule in orientation 2. The
surface accounts for the van-der Waals radii of atoms.
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Figure 74: Computation of molecular cross-sectional area for HPMC
A. Measured dimensions (bond length measuring length and breadth) for Orientation 1 of the
molecule. B. Measured dimensions for orientation 2 of the molecule. C. Surface constructed for
the molecule in orientation 1. D. Surface constructed for the molecule in orientation 2. The
surface accounts for the van-der Waals radii of atoms.
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Figure 75: Computation of molecular cross-sectional area for Mono-Tab
A. Measured dimensions (bond length measuring length and breadth) for Orientation 1 of the
molecule. B. Measured dimensions for orientation 2 of the molecule. C. Surface constructed for
the molecule in orientation 1. D. Surface constructed for the molecule in orientation 2. The
surface accounts for the van-der Waals radii of atoms.
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Figure 76: Computation of molecular cross-sectional area for starch
A. Measured dimensions (bond length measuring length and breadth) for Orientation 1 of the
molecule. B. Measured dimensions for orientation 2 of the molecule. C. Surface constructed for
the molecule in orientation 1. D. Surface constructed for the molecule in orientation 2. The
surface accounts for the van-der Waals radii of atoms.
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Figure 77: Computation of molecular cross-sectional area for talc
A. Measured dimensions (bond length measuring length and breadth) for Orientation 1 of the
molecule. B. Measured dimensions for orientation 2 of the molecule. C. Surface constructed for
the molecule in orientation 1. D. Surface constructed for the molecule in orientation 2. The
surface accounts for the van-der Waals radii of atoms.
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Figure 78: Computation of molecular cross-sectional area for Tri-Tab®
A. Measured dimensions (bond length measuring length and breadth) for Orientation 1 of the
molecule. B. Measured dimensions for orientation 2 of the molecule. C. Surface constructed for
the molecule in orientation 1. D. Surface constructed for the molecule in orientation 2. The
surface accounts for the van-der Waals radii of atoms.
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